Holder for electrically charging a substrate during coating

Description

BACKGROUND OF THE INVENTION

It is often beneficial to provide coatings onto substrates, such that the surfaces of such substrates have desired properties or effects.

For example, it is useful to coat biomedical implants to provide for the localized delivery of pharmaceutical or biological agents to target specific locations within the body, for therapeutic or prophylactic benefit. One area of particular interest is drug eluting stents (DES) that has recently been reviewed by Ong and Serruys in Nat. Clin. Pract. Cardiovasc. Med., (December 2005), Vol 2, No 12, 647. Typically such pharmaceutical or biological agents are co-deposited with a polymer. Such localized delivery of these agents avoids the problems of systemic administration, which may be accompanied by unwanted effects on other parts of the body, or because administration to the afflicted body part requires a high concentration of pharmaceutical or biological agent that may not be achievable by systemic administration. The coating may provide for controlled release, including long-term or sustained release, of a pharmaceutical or biological agent. Additionally, biomedical implants may be coated with materials to provide beneficial surface properties, such as enhanced biocompatibility or lubriciousness.

Conventional solvent-based spray coating processes are hampered by inefficiencies related to collection of the coating constituents onto the substrate and the consistency of the final coating. As the size of the substrate decreases, and as the mechanical complexity increases, it grows increasingly difficult to uniformly coat all surfaces of a substrate.

A cost-effective method for depositing inert polymers and pharmaceutical or biological agents onto a substrate, where the collection process is efficient, the coating produced is conformal, substantially defect-free and uniform, the composition of the coating can be regulated and the morphology and/or secondary structure of the pharmaceutical or biological agents can be controlled is described in PCT/US 06/027,321, incorporated herein by reference in its entirety. The method permits structural and morphological preservation of the agents deposited during the coating process. The method as described in PCT/U.S. 06/027,321 contemplates electrically charging the stent and creating an electrical field around the stent and stent holder during the coating method.

What is needed, therefore, is a stent holder which mounts and electrically charges a stent.

SUMMARY OF THE INVENTION

The present invention relates to a holder for mounting and electrically charging a stent during a coating process, an assembly for coupling, supporting, and electrically charging the stent holder, a chamber for controlling the electrical field around the stent and providing a platform for coating a stent, and a method of coating a stent using the electrically charged holder, electrically charged assembly, and chamber.

In one aspect, the invention provides a stent holder for removably holding a stent during a coating process wherein the stent holder charges the stent during the coating process. In one embodiment the holder forms an electrical field around the stent. In another embodiment the holder comprises a mask for masking at least a part of the stent. In another embodiment the holder comprising a support interfacing portion for interfacing with a support, wherein the support supports and electrically charges the support interfacing portion. In another embodiment, the stent holder comprises a stent mounting portion that electrically charges the stent. In another embodiment the stent mounting portion the stent mounting portion has a configuration whereby the stent slides over an elliptical portion of the stent holder. In another embodiment the stent mounting portion has a collapsed and an expanded state for minimizing coating damage during mounting or removal of the stent. In another embodiment the stent sits on an electrically chargeable section of the stent mounting portion. In another embodiment the stent mounting portion comprises a spring section. In another embodiment, the stent mounting portion comprises threads winding around a central axis. In another embodiment the threads are non-conductive. In another embodiment the threads are electrically chargeable. In another embodiment the holder further comprises a member for manipulating the electrical field around the stent. In other embodiments, the holder is in varied configurations capable of mounting and electrically charging the stent and creating an electrical field around the stent.

In one aspect, the invention provides an assembly comprising: at least one stent holder for removably holding a stent during a coating process wherein the stent holder charges the stent during the coating process; and a support for supporting the at least one stent holder, wherein the support electrically charges the stent holder. In one embodiment, the stent holder of the assembly comprises a support interfacing portion for interfacing with the support, wherein the support supports and electrically charges the support interfacing portion. In another embodiment, the support of the assembly comprises at least one coupling portion for electrically coupling to the support interfacing portion of the stent holder. In another embodiment, the support of the assembly comprises a charging portion connected to an electrical source. In other embodiments, the coupling portion is in varied configurations capable of electrically charging and supporting the holder.

In one aspect, the invention provides a chamber for a stent coating process wherein the chamber comprises:

- a base comprising a first hole;
- an assembly comprising: at least one stent holder for removably holding a stent during a coating process wherein the stent holder charges the stent during the coating process, and a support for supporting the at least one stent holder, wherein the support electrically charges the stent holder; and
- a coating nozzle for coating the stent held by the assembly,

wherein the assembly sits on the base, wherein the first base hole provides the coating nozzle access to the chamber for coating the stent, and wherein the coating nozzle is removably fitted in the first base hole. In one embodiment, the chamber further comprises at least one grounded member connected to a ground source. In another embodiment, a grounded member is removably fitted in the first or a second base hole. In another embodiment, the chamber further comprises a purge nozzle for purging the chamber, wherein the purge nozzle is fitted in the first, the second, or a third base hole. In another embodiment, the chamber further comprises an insulating stand for insulating the base from the electrical charge of the assembly, wherein the assembly sits on the insulating stand, and the insulating stand sits on the base, and wherein the insulating stand has at least one hole aligning with the first, the second, the third, or a fourth base hole. In another embodiment, the chamber further comprises a cover that fits over the assembly and sits on the base. In another embodiment, the chamber further comprises at least one insulating grounded member outside the cover, wherein the insulating grounded member is connected to a ground source and removably sits on the base. In other embodiments, the cover is transparent, comprises an insulator material, and/or is disposable. In other embodiments, the base has non-conductive properties, and/or is a thermoformed plastic part. In another embodiment, the chamber comprises an electrical source connected to the support of the assembly. In another embodiment, the assembly of the chamber comprises a plurality of stent holders arranged in a circular configuration, and wherein the coating nozzle is positioned within the circular configuration formed by the holders.

In one aspect, the invention provides a method of coating a plurality of stents wherein the method comprises:

- providing an assembly comprising a support and a plurality of stent holders, wherein the stent holders are arranged in a circular configuration, and wherein a coating nozzle is positioned within the circular configuration formed by the stent holders;
- mounting the stents onto the stent holders;
- electrically charging the stents by electrically charging the support which electrically charges the stent holder upon which the stents are mounted; and
- exposing the electrically charged stents to coating particles from the coating nozzle wherein the electrically charged stents attract the coating particles and wherein the coating particles deposit on the stents while maintaining the stents stationary during coating.

INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments and the accompanying drawings of which:

FIG. 1A to 1B shows a chamber of the invention within a coating system.

FIG. 1C shows a chamber of the invention.

FIG. 2A shows an electrical field surrounding a stent and stent holder when charged within a chamber.

FIG. 2B shows the electric potential across the length of the chamber when the electrical field of FIG. 2A surrounds a stent and stent holder when charged within a chamber.

FIG. 2C shows an electrical field surrounding a stent and stent holder when charged within a chamber.

FIG. 2D shows the electric potential across the length of the chamber when the electrical field of FIG. 2C surrounds a stent and stent holder when charged within a chamber.

FIGS. 2E and 2F show top views of electrical fields surrounding a plurality of stents and stent holders when charged within a chamber.

FIGS. 3A and 3B illustrate a stent holder in accordance with an embodiment of the invention and a stent, the stent holder having a stent mounting portion in Configuration A and a support interfacing portion;

FIGS. 4A and 4B illustrate a stent holder in accordance with an embodiment of the invention and a stent, the stent holder having a stent mounting portion in Configuration B and a support interfacing portion;

FIGS. 5A and 5B illustrate a stent holder in accordance with an embodiment of the invention and a stent, the stent holder having a stent mounting portion in Configuration C and a support interfacing portion;

FIGS. 6A and 6B illustrate a stent holder in accordance with an embodiment of the invention, the stent holder having a mask and a stent mounting portion in Configuration C and a support interfacing portion;

FIGS. 7A and 7B illustrate a stent holder in accordance with an embodiment of the invention and a stent, the stent holder having a stent mounting portion in Configuration D and a support interfacing portion;

FIG. 8 illustrates a stent holder in accordance with an embodiment of the invention and a stent, the stent holder having a stent mounting portion in Configuration E, a support interfacing portion, and showing, in phantom lines, expansion of the stent mounting portion;

FIGS. 9A and 9B illustrate a stent holder in accordance with an embodiment of the invention and a stent, the stent holder having a stent mounting portion in Configuration F and a support interfacing portion;

FIG. 10 illustrates a stent holder in accordance with an embodiment of the invention and a stent, the stent holder having a stent mounting portion in Configuration G and a support interfacing portion.

FIG. 11 illustrates a stent holder in accordance with an embodiment of the invention and a stent, the stent holder having a stent mounting portion in Configuration H and a support interfacing portion;

FIG. 12 illustrates a stent holder in accordance with an embodiment of the invention and a stent, the stent holder having a stent mounting portion in Configuration I and a support interfacing portion;

FIG. 13 illustrates a top view of the stent holder embodiment of FIG. 12 and stent;

FIG. 14 illustrates a stent holder in accordance with an embodiment of the invention, the stent holder having a stent mounting portion in Configuration J and a support interfacing portion;

FIG. 15 illustrates a stent holder in accordance with an embodiment of the invention, the stent holder having a stent mounting portion in Configuration K and a support interfacing portion;

FIG. 16 illustrates a stent holder in accordance with an embodiment of the invention with a mounted stent, the stent holder having a stent mounting portion in Configuration A as shown in FIG. 3A, and having a support interfacing portion in Configuration L;

FIG. 17 illustrates a stent holder in accordance with an embodiment of the invention with a mounted stent, the stent holder having a stent mounting portion in Configuration A as shown in FIG. 3A, and having a support interfacing portion in Configuration M;

FIG. 18 illustrates a stent holder in accordance with an embodiment of the invention with a mounted stent, the stent holder having a stent mounting portion in Configuration A as shown in FIG. 3A, and having a support interfacing portion in Configuration N;

FIG. 19 illustrates a stent holder in accordance with an embodiment of the invention with a mounted stent, the stent holder having a stent mounting portion in Configuration A as shown in FIG. 3A, and having a support interfacing portion in Configuration O;

FIG. 20 illustrates a stent holder in accordance with an embodiment of the invention with a mounted stent, the stent holder having a stent mounting portion in Configuration A as shown in FIG. 3A, and having a support interfacing portion in Configuration P;

FIG. 21 illustrates a stent holder in accordance with an embodiment of the invention with a mounted stent, the stent holder having a stent mounting portion in Configuration A as shown in FIG. 1A, and having a support interfacing portion in Configuration Q;

FIG. 22 is an exploded view of an assembly in accordance with an embodiment of the invention, having a stent holder as shown in FIG. 3A, the stent holder having a stent mounting portion in Configuration A as shown in FIG. 3A, and a support interfacing portion in Configuration P as shown in FIG. 20;

FIG. 23 illustrates a cross sectional view along line A-A of FIG. 22 of the support of an assembly in accordance with an embodiment of the invention, the support having a support coupling portion in Configuration R;

FIG. 24 illustrates a cross sectional view along line A-A of FIG. 22 of the support of an assembly in accordance with an embodiment of the invention, the support having a support coupling portion in Configuration S;

FIG. 25 illustrates a cross sectional view along line A-A of FIG. 22 of the support of an assembly in accordance with an embodiment of the invention, the support having a support coupling portion in Configuration T;

FIG. 26 illustrates a cross sectional view along line A-A of FIG. 22 of the support of an assembly in accordance with an embodiment of the invention, the support having a support coupling portion in Configuration U; and

FIG. 27 is an exploded view of a chamber in accordance with an embodiment of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is explained in greater detail below. This description is not intended to be a detailed catalog of all the different ways in which the invention may be implemented, or all the features that may be added to the instant invention. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the instant invention. Hence, the following specification is intended to describe some particular embodiments of the invention, including the preferred embodiment, and not to exhaustively specify all permutations, combinations and variations thereof. The details of the embodiment may be changed without departing from the invention, which is defined by the claims.

Applicants specifically intend that all United States patent references cited herein be incorporated herein by reference in their entirety.

1. The Stent Holder

FIGS. 3A to 21 illustrate various stent holders for removably holding and electrically charging a stent during a coating process. The holders form electrical fields around the stents, embodiments of the fields shown in FIGS. 2A through 2F, which results in attraction of non-charged coating particles to the charged stent during the coating process. Any of the holders can be further configured with a conductive member in order to manipulate the electrical field around the stent. Examples of suitable conductive materials to conduct a charge from the holders to the stent include, but are not limited to, stainless steel and shape memory metal alloys, such as Nitinol (a Ni—Ti alloy).

FIGS. 3A to 6B show a stent (4) mounted on a stent holder (1) having a stent mounting portion (2), as shown, and a support interfacing portion (3). The stent mounting portion (2) has both an expanded and a collapsed state, and comprises at least two arms (30) upon which the stent (4) is mounted. In its expanded state, the stent mounting portion (2) has an outer distance, shown by double headed arrow (33), which is approximately equal to stent inner diameter, shown by double headed arrow (10). The stent mounting portion (2) in its expanded state exerts force on the inner surface of the stent in opposing directions, thereby holding the stent (4) in place, while minimizing stent deformation. When the first end (31) of the stent holder (1) and the second end (32) of the stent holder (1) are moved in opposite directions simultaneously, or the first end (31) is fixed and the second end (32) is moved away from the first end (31), the distance between the arms (30) reduces. This allows the stent (4) to be loaded onto the stent holder (1), or, alternatively, released from the stent holder (1) if already mounted by reducing contact between the stent (4) and the stent holder (1). The arms (30) are made of conductive material and conduct an electrical charge to the stent (4) when the arms (1) touch the stent (4).

In the embodiment of FIGS. 3A and 3B, the stent mounting portion Configuration A has arms (30) that comprise an elliptical portion.

In another embodiment, the stent holder (1) has a stent mounting portion (2) in Configuration A, as shown in FIG. 3A, and a support interfacing portion (3), comprises at least two arms (30) upon which the stent (4) is mounted, without the stent mounting portion collapsed state of FIG. 3B. The stent (4) may be slid along the arms to be mounted and released from the stent holder (1).

In the embodiment of FIGS. 4A and 4B, the stent mounting portion Configuration B has arms (30) extending from a central axis of the stent holder, making at least one bend, and returning to the central axis of the stent holder. In this embodiment, the number of contact points (36) between the stent (4) and the stent holder (1) is at least two.

In the embodiment of FIGS. 5A and 5B, the stent mounting portion Configuration C has arms (30) extending from a central axis of the stent holder (1) and arcing to return to the central axis of the stent holder (1).

The embodiment of FIGS. 6A and 6B show a stent holder (1) having a stent mounting portion (2) in Configuration C and further comprising a mask (5). The mask (5) provides masking of the inner surface of the stent (4) so as to reduce and/or eliminate coating of the stent inner surface. Examples of suitable materials for the mask (5) include non-conductive materials, polymers, and/or non-stick materials such as polytetrafluoroethylene (e.g., TEFLON), and/or other non-conducting materials.

FIGS. 7A and 7B show a stent (4) mounted on a stent holder (1) having a stent mounting portion (2) in Configuration D, and a support interfacing portion (3). The stent mounting portion (2) Configuration D has both an expanded and a collapsed state, and comprises at least two arms (30) having free ends (35) upon which the stent (4) is mounted. In its expanded state, the stent mounting portion (2) has an outer distance, shown by double headed arrow (33), which is equal to or greater than the stent inner diameter, shown by double headed arrow (10). The stent mounting portion (2) in its expanded state exerts force on the inner surface of the stent in opposing directions and/or protrudes into a stent gap, thereby holding the stent (4) in place. When the arm free ends (35) are moved toward each other, the distance between the arm free ends (33) reduces. This allows the stent (4) to be loaded onto the stent holder (1), or, alternatively, released from the stent holder (1) if already mounted by reducing contact between the stent (4) and the stent holder (1). The arms (30) are made of conductive material and conduct an electrical charge to the stent (4) when the arms (30) touch the stent (4).

FIG. 8 shows a stent (4) mounted on a stent holder (1) having a stent mounting portion (2) in Configuration E, as shown, and a support interfacing portion (3). The stent mounting portion (2) comprises two arms (30) upon which the stent (4) is mounted. The stent mounting portion (2) in this embodiment can move or be moved between in an expanded state and a collapsed state by means of a spring section (6). The expanded state is shown in phantom lines. In its expanded state, the stent mounting portion (2) has an outer distance, shown by double headed arrow (33), which is equal to or greater than the stent inner diameter, shown by double headed arrow (10). The stent mounting portion (2) in its expanded state exerts forces on the inner surface of the stent in opposing directions, thereby holding the stent (4) in place. When the stent mounting portion distance (33) is reduced, manually or otherwise by moving the arms (30) toward each other, the stent (4) may be loaded onto the stent holder (1), or, alternatively, the stent (4) may be released from the stent holder (1) if already mounted, with reduced friction between the stent (4) and the stent holder (1). The arms (30) are made of conductive material and conduct an electrical charge to the stent (4) when the arms (1) touch the stent (4).

FIGS. 9A and 9B shows a stent (4) mounted on a stent holder (1) having a stent mounting portion (2) in Configuration F, as shown, and a support interfacing portion (3). The stent mounting portion (2) in this embodiment can move or be moved between in an expanded state and a collapsed state by means of a spring section (6). When the spring ends (37) and (38) are moved in opposite directions simultaneously, or the first end (37) of the spring is fixed and the second end (38) of the spring is moved away from the first end, or the opposite, the spring diameter (39) reduces. This allows the stent (4) to be loaded onto the stent holder (1), or, alternatively, released from the stent holder (1) if already mounted by reducing contact between the stent (4) and the stent holder (1). The spring ends (37) and (38) are made of conductive material, and conduct an electrical charge to the stent (4) when the arms (1) touch the stent (4).

FIG. 10 shows a stent (4) mounted on a stent holder (1) having a stent mounting portion (2) in Configuration G, as shown, a support interfacing portion (3), and a removable cap (7). When the cap (7) is removed from the stent holder (1), a stent (4) can be mounted on the stent holder (1) by resting one end of the stent (4) on the stent mounting portion (2) of the stent holder (1), and replacing the cap (7) such that the opposite end of the stent (4) is also held by the cap (7) such that the stent central axis aligns with the central axis of the stent holder (1).

FIG. 11 shows a stent (4) mounted on a stent holder (1) having a stent mounting portion (2) in Configuration H, as shown, a support interfacing portion (3), a mask (5) for masking at least part of the stent inner surface, and an electrically chargeable section (8). In this embodiment, the electrically chargeable section (8) has a larger outer diameter, shown by double headed arrow (9), than the stent inner diameter, shown by double headed arrow (41), whereby, when mounted, the stent (4) sits on the electrically chargeable section (8). Examples of suitable materials for the mask (5) include non-conductive materials, polymers, and/or non-stick materials such as polytetrafluoroethylene (e.g., TEFLON).

In another embodiment, a variation of the embodiment of FIG. 1, the electrically chargeable section (8) has an outer diameter (9) that is approximately equivalent to the stent outer diameter (41), whereby, when mounted, the stent (4) extends over at least a part of the electrically chargeable section (8) and touches the electrically chargeable section (8).

FIG. 12 shows a stent (4) mounted on a stent holder (1) having a stent mounting portion (2) in Configuration I, as shown, a support interfacing portion (3), a mask (5) for masking at least part of the stent inner surface, and an electrically chargeable section (8) comprising an electrically chargeable rod (42) extending the length of the stent (4). In this embodiment, the stent (4) extends over and touches the electrically chargeable rod (42). Examples of suitable materials for the mask (5) include non-conductive materials, polymers, and/or non-stick materials such as polytetrafluoroethylene (e.g., TEFLON).

FIG. 13 shows a top view of the stent holder (1) embodiment of FIG. 12 and stent (4).

FIG. 14 shows a stent (4) mounted on a stent holder (1) having a stent mounting portion (2) in Configuration J, as shown, a support interfacing portion (3), a mask (5) for masking at least part of the stent inner surface, and an electrically chargeable section (8) comprising electrically chargeable threads (11) winding around the stent holder central axis, shown in phantom (43). Examples of suitable materials for the mask (5) include non-conductive materials, polymers, and/or non-stick materials such as polytetrafluoroethylene (e.g., TEFLON).

FIG. 15 shows a stent (4) mounted on a stent holder (1) having a stent mounting portion (2) in Configuration K, as shown, a support interfacing portion (3), a mask (5) for masking at least part of the stent inner surface, and an electrically chargeable section (8) wherein the stent mounting portion comprises non-conductive threads (44) winding around the stent holder central axis, shown in phantom (43). Examples of suitable materials for the mask (5) and for the non-conductive threads (44) include non-conductive materials, polymers, and/or non-stick materials such as polytetrafluoroethylene (e.g., TEFLON).

In another embodiment, a variation of FIG. 15, the mask (5) is spaced apart from the stent (4) to control the amount and/or the quality of the inner surface coating.

FIGS. 16 to 21 show a stent (4) mounted on a stent holder (1), the stent holder (1) having a stent mounting portion (2) of Configuration A, and having a support interfacing portion (3) of varying configurations. In alternative embodiments, the stent mounting portion (2) is any of Configurations A through K, or other embodiments within the scope of this invention. The support interfacing portion (3) comprises a conductive material and is electrically charged by a support 12. Examples of suitable conductive materials to conduct a charge from the holders to the stent include, but are not limited to, stainless steel and shape memory metal alloys, such as Nitinol (a Ni—Ti alloy).

In FIGS. 16 to 19 the support interfacing portion (3) of these embodiments has an expanded state and comprises at least one arm (30) which supports and electrically couples the stent holder (1) to a support coupling portion (13) of a support (12). In other embodiments, the support interfacing portion (3) also has a collapsed state. In the embodiments of FIGS. 16 to 19, the support interfacing portion (3) in its expanded state exerts force on the inner surface of the support coupling portion (13) of a support (12) in opposing directions, thereby holding the stent holder (1) in place.

In the embodiment of FIG. 16, the support interfacing portion Configuration L has an arm (30) that comprises portions approximately parallel to each other.

In the embodiment of FIG. 17, the support interfacing portion Configuration M has an arm (30) extending from a central axis of the stent holder (1), making a plurality of bends, and returning to the central axis of the stent holder. In the embodiment depicted in FIG. 17, the number of contact points (36) between the support interfacing portion (3) and the support coupling portion (13) of the support (12) is two. Alternative embodiments may change the number of contact points by changing the geometry of the support interfacing portion.

In the embodiment of FIG. 18, the support interfacing portion is in Configuration N and an arm (30) extending from a central axis of the stent holder and arcing to return to the central axis of the stent holder (1).

FIG. 19 illustrates a stent holder (1) having a stent mounting portion (2) in Configuration A as shown in FIG. 3A, and having a support interfacing portion (3) in Configuration O. The support interfacing portion (3) comprises a spring section (6) which electrically couples the stent holder (1) to the support (12) by removably mating with the support coupling portion (13) of the support (12).

FIG. 20 illustrates a stent holder (1) having a stent mounting portion (2) in Configuration A as shown in FIG. 3A, and having a support interfacing portion (3) in Configuration P. In alternative embodiments of the invention, the support interfacing portion comprises a pin, rod, mandrel, or wire.

In the embodiment of FIG. 21 illustrates a stent holder (1) having a support interfacing portion in Configuration Q, wherein the support interfacing portion (3) is a tube for mating with the support coupling portion (13) of a support (12).

2. The Assembly

FIGS. 22 to 26 illustrate various embodiments of an assembly comprising at least one stent holder for removably holding and electrically charging a stent during a coating process, and a support for supporting the at least one stent holder, wherein the support electrically charges the stent holder. The support is charged by an electrical source. The stent holder is coupled to a support, thereby transferring the electrical charge of the support to the stent holder. The electrical charge of the stent holder is transferred to the mounted stent. The electrically charged holders form electrical fields around the stents which results in attraction of non-charged coating particles to the charged stent during the coating process. The stent holders can be selected from any appropriately mating stent holder support interfacing portion embodiments noted in this specification, and any embodiments that those of skill in the art will be readily able to apply without departing from the scope of the claims hereto attached. Examples of suitable conductive materials for the support in order to conduct a charge from the electrical source to the stent holder include, but are not limited to, stainless steel and shape memory metal alloys, such as Nitinol (a Ni—Ti alloy).

FIG. 22 is an exploded view of an assembly (15) in accordance with an embodiment of the invention. In this embodiment, the assembly (15) comprises: at least one stent holder (1) comprising a stent mounting portion (2) in Configuration A as shown in FIG. 3A, and a support having a support interfacing portion in Configuration P as shown in FIG. 20. The support (12) supports the stent holder (1) and electrically charges the stent holder (1). The stent holder (1) removably holds a stent (4) during a coating process and charges the stent (4).

In another embodiment of the assembly (15), a single support (12) comprises a plurality of stent holders (1). In another embodiment, the assembly (15) comprises a support (12) having a plurality of support coupling portions (13) arranged in a circular configuration, and a plurality of stent holders (1) corresponding to the support coupling portion (13) configuration. A central hole of the support (12) provides coating equipment access to the mounted and charged stents (4). Example coating equipment comprises coating nozzles, purging nozzles, electrical field manipulation members, and grounding members.

FIGS. 23 to 26 show embodiments of support coupling portions (13) of a support (12) of an assembly (15), wherein the support coupling portions (13) removably couple and electrically charge a stent holder 1.

FIG. 23 illustrates a cross sectional view of the support (12) of an assembly (15) along line A-A of FIG. 22 in accordance with an embodiment of the invention, the support (15) comprising a support coupling portion (13) in Configuration R. The support coupling portion (13) of FIG. 23 comprises a hole, a bore or a tube within the support. Non-exhaustive examples of stent holder support interfacing portions which appropriately mate with this embodiment are Configurations L, M, N, 0, and P of FIGS. 16 to 20, respectively.

FIG. 24 illustrates a cross sectional view of the support (12) of an assembly (15) along line A-A of FIG. 22 in accordance with an embodiment of the invention, the support (12) comprising a support coupling portion (13) in Configuration S. The support coupling portion (13) of FIG. 24 comprises tube at least a portion of which is outside the support. In this embodiment the support coupling portion (13) is on the top of the support (12). Non-exhaustive examples of stent holder support interfacing portions which appropriately mate with this embodiment are Configurations L, M, N, 0, and P of FIGS. 16 to 20, respectively.

FIG. 25 shows a cross sectional view of the support (12) of an assembly (15) along line A-A of FIG. 22 in accordance with an embodiment of the invention, the support (12) comprising a support coupling portion (13) in Configuration T. In this embodiment, similar to the embodiment of FIG. 24, the support coupling portion (13) of FIG. 25 comprises tube at least a portion of which is outside the support (12). In the embodiment shown in FIG. 25, the support coupling portion (13) is on the side of the support (12). Non-exhaustive examples of stent holder (1) support interfacing portions (3) which appropriately mate with this embodiment are Configurations L, M, N, 0, and P of FIGS. 16 to 20, respectively.

FIG. 26 illustrates a cross sectional view along line A-A of FIG. 22 of the support (12) of an assembly (15) in accordance with an embodiment of the invention, the support (12) having a support coupling portion (13) in Configuration U. In this embodiment, the support coupling portion (13) comprises a conductive wire, rod, mandrel or similar supporting conductive member. A non-exhaustive example of a stent holder (1) support interfacing portion (3) which appropriately mates with this embodiment is Configuration Q of FIG. 21.

While the description is presented in terms of the preferred embodiment, a vascular stent, the invention may be directed to any type of substrate selected from the group consisting of stents, joints, screws, rods, pins, plates, staples, shunts, clamps, clips, sutures, suture anchors, electrodes, catheters, leads, grafts, dressings, pacemakers, pacemaker housings, cardioverters, cardioverter housings, defibrillators, defibrillator housings, prostheses, ear drainage tubes, ophthalmic implants, orthopedic substrates, vertebral disks, bone substitutes, anastomotic substrates, perivascular wraps, colostomy bag attachment substrates, hemostatic barriers, vascular implants, vascular supports, tissue adhesives, tissue sealants, tissue scaffolds and intraluminal substrates. In another embodiment, the assembly comprises the substrate, wherein the substrate is mounted on a substrate holder, wherein the substrate holder electrically charges the substrate, and wherein the substrate holder is supported by a support, wherein the support electrically charges the substrate holder, the support comprising substrate holder coupling portions for electrically charging the substrate holder.

3. The Chamber

FIG. 27 is an exploded view of a chamber (17) for a stent coating process in accordance with one embodiment of the invention. This chamber (17) embodiment comprises:

- a base (18) comprising at least one hole (19);
- an assembly (15) comprising: at least one stent holder (1) for removably holding a stent (4) during a coating process wherein the stent holder (1) charges the stent (4) during the coating process, and a support (12) for supporting the at least one stent holder (1), wherein the support (12) electrically charges the stent holder (1);
- and a coating nozzle (20) for coating the stent (4) held by the assembly (15),
  
  wherein the assembly (15) sits on the base (18), wherein the hole (19) in the base (18) provides the coating nozzle (20) access to the chamber (17) for coating the stent (4), and wherein the coating nozzle (20) is removably fitted in the base hole (19).

This embodiment further comprises at least one grounded member (21) connected to a ground source, wherein the at least one grounded member (21) is removably fitted in a base hole (19). The chamber (17) embodiment shown in FIG. 27 further comprises a purge nozzle (23) for purging the chamber (17), wherein the purge nozzle (23) is fitted in a base hole (19). The embodiment further comprises an insulating stand (26) for insulating the base (18) from the electrical charge of the assembly (15), wherein the assembly (15) sits on the insulating stand (26), and the insulating stand (26) sits on the base (18), and wherein the insulating stand (26) has a hole (27) aligning with a base hole (19). The embodiment further comprises a cover (24) that fits over the assembly (15) and sits on the base (18), and comprises an insulating grounded member (44) outside the cover (24), wherein the insulating grounded member (44) is connected to a ground source and removably sits on the base (18). In this embodiment, the cover (24) is transparent, comprises an insulator material, and is disposable. The base (18) has non-conductive properties and is a thermoformed plastic part. The chamber (17) comprises an electrical source (25) connected to the support (12) of the assembly. In another embodiment, the assembly (15) of the chamber (17) comprises a plurality of stent holders (1) arranged in a circular configuration and wherein the coating nozzle (20) is positioned within the circular configuration formed by the holders (1).

- an assembly comprising: a substrate holder, wherein a substrate is removably mounted on the substrate holder, wherein the substrate holder electrically charges the substrate; a support, wherein support supports the substrate holder and wherein the support electrically charges the substrate holder, and wherein the support comprises a substrate holder coupling portion for electrically charging the substrate holder;
- a mounted substrate, wherein the substrate is electrically charged;
- a base comprising a first hole;
- and a coating nozzle for coating the substrate held by the assembly,
  
  wherein the assembly sits on the base, wherein the hole in the base provides the coating nozzle access to the chamber for coating the substrate, and wherein the coating nozzle is removably fitted in the first hole.

In another embodiment, the chamber further comprises at least one grounded member connected to a ground source, wherein the at least one grounded member is removably fitted in the first or a second base hole. In another embodiment, the chamber further comprises a purge nozzle for purging the chamber, wherein the purge nozzle is fitted in the first, the second, or a third base hole. In another embodiment, the chamber further comprises an insulating stand for insulating the base from the electrical charge of the assembly, wherein the assembly sits on the insulating stand, and the insulating stand sits on the base, and wherein the insulating stand has a hole aligning with the first, the second, the third, or a fourth base hole. In another embodiment, the chamber further comprises a cover that fits over the assembly and sits on the base, and comprises an insulating grounded member outside the cover, wherein the insulating grounded member is connected to a ground source and removably sits on the base. In another embodiment, the cover is transparent, comprises an insulator material, and is disposable. In another embodiment, the base has non-conductive properties and is a thermoformed plastic part.

In another embodiment, the chamber comprises an electrical source connected to the support of the assembly.

In another embodiment of the chamber, the assembly comprises a plurality of substrate holders arranged in a circular configuration, and wherein the coating nozzle is positioned within the circular configuration formed by the holders.

4. The Method

In one aspect, the invention provides a method of coating a plurality of stents wherein the method comprises:

- providing an assembly comprising a support and a plurality of stent holders, wherein the stent holders are arranged in a circular configuration, and wherein a coating nozzle is positioned within the circular configuration formed by the stent holders;
- mounting the stents onto the stent holders;
- electrically charging the stents by electrically charging the support which electrically charges the stent holder upon which the stents are mounted; and
- exposing the electrically charged stents to coating particles from the coating nozzle wherein the electrically charged stents attract the coating particles and wherein the coating particles deposit on the stents while maintaining the stents stationary during coating.

In another embodiment, the coating particles comprise inert polymers, pharmaceutical or biological agents. In another embodiment, the coating particles and exposure of the stent to the coating particles comprise the embodiments as described in PCT/U.S. 06/027,321.

While the description is presented in terms of the preferred embodiment, a vascular stent, the invention may be directed to any type of substrate selected from the group consisting of stents, joints, screws, rods, pins, plates, staples, shunts, clamps, clips, sutures, suture anchors, electrodes, catheters, leads, grafts, dressings, pacemakers, pacemaker housings, cardioverters, cardioverter housings, defibrillators, defibrillator housings, prostheses, ear drainage tubes, ophthalmic implants, orthopedic substrates, vertebral disks, bone substitutes, anastomotic substrates, perivascular wraps, colostomy bag attachment substrates, hemostatic barriers, vascular implants, vascular supports, tissue adhesives, tissue sealants, tissue scaffolds and intraluminal substrates. In one embodiment, the invention provides a method of coating a plurality of substrates wherein the method comprises:

- providing an assembly comprising a support and a plurality of substrate holders, wherein the substrate holders are arranged in a circular configuration, and wherein a coating nozzle is positioned within the circular configuration formed by the substrate holders;
- mounting the substrates onto the substrate holders;
- electrically charging the substrates by electrically charging the support which electrically charges the substrate holder upon which the substrates are mounted; and
- exposing the electrically charged substrates to coating particles from the coating nozzle wherein the electrically charged substrates attract the coating particles and wherein the coating particles deposit on the substrates while maintaining the substrates stationary during coating.

5. Definitions

As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.

“Substrate” as used herein, refers to any surface upon which it is desirable to deposit a coating comprising a polymer and a pharmaceutical or biological agent, wherein the coating process does not substantially modify the morphology of the pharmaceutical agent or the activity of the biological agent. Biomedical implants are of particular interest for the present invention; however the present invention is not intended to be restricted to this class of substrates. Those of skill in the art will appreciate alternate substrates that could benefit from the coating process described herein, such as pharmaceutical tablet cores, as part of an assay apparatus or as components in a diagnostic kit (e.g. a test strip).

“Biomedical implant” as used herein refers to any implant for insertion into the body of a human or animal subject, including but not limited to stents (e.g., vascular stents, peripheral stents), electrodes, catheters, leads, implantable pacemaker, cardioverter or defibrillator housings, joints, screws, rods, ophthalmic implants, femoral pins, bone plates, grafts, anastomotic devices, perivascular wraps, sutures, staples, shunts for hydrocephalus, dialysis grafts, colostomy bag attachment devices, ear drainage tubes, leads for pace makers and implantable cardioverters and defibrillators, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, vascular implants, tissue adhesives and sealants, tissue scaffolds, various types of dressings (e.g., wound dressings), bone substitutes, intraluminal devices, vascular supports, etc.

The implants may be formed from any suitable material, including but not limited to organic polymers (including stable or inert polymers and biodegradable polymers), metals, inorganic materials such as silicon, and composites thereof, including layered structures with a core of one material and one or more coatings of a different material. Substrates made of a conducting material facilitate electrostatic capture. However, the invention contemplates the use of electrostatic capture in conjunction with substrate having low conductivity or which non-conductive. To enhance electrostatic capture when a non-conductive substrate is employed, the substrate is processed while maintaining a strong electrical field in the vicinity of the substrate.

Subjects into which biomedical implants of the invention may be applied or inserted include both human subjects (including male and female subjects and infant, juvenile, adolescent, adult and geriatric subjects) as well as animal subjects (including but not limited to dog, cat, horse, monkey, etc.) for veterinary purposes.

In a preferred embodiment the biomedical implant is an expandable intraluminal vascular graft or stent (e.g., comprising a wire mesh tube) that can be expanded within a blood vessel by an angioplasty balloon associated with a catheter to dilate and expand the lumen of a blood vessel, such as described in U.S. Pat. No. 4,733,665 to Palmaz Shaz. In another embodiment the biomedical implant is a self-expanding intraluminal vascular stent (e.g., comprising a memory metal such as Ni—Ti, or Nitinol) that can be delivered with a catheter to dilate and expand the lumen of a blood vessel.

“Polymer” as used herein, refers to a series of repeating monomeric units that have been cross-linked or polymerized. Any suitable polymer can be used to carry out the present invention. It is possible that the polymers of the invention may also comprise two, three, four or more different polymers. In some embodiments of the invention only one polymer is used. In some preferred embodiments a combination of two polymers are used. Combinations of polymers can be in varying ratios, to provide coatings with differing properties. Those of skill in the art of polymer chemistry will be familiar with the different properties of polymeric compounds. Examples of polymers that may be used in the present invention include, but are not limited to polycarboxylic acids, cellulosic polymers, proteins, polypeptides, polyvinylpyrrolidone, maleic anhydride polymers, polyamides, polyvinyl alcohols, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters, polyurethanes, polystyrenes, copolymers, silicones, polyorthoesters, polyanhydrides, copolymers of vinyl monomers, polycarbonates, polyethylenes, polypropylenes, polylactic acids, polyglycolic acids, polycaprolactones, polyhydroxybutyrate valerates, polyacrylamides, polyethers, polyurethane dispersions, polyacrylates, acrylic latex dispersions, polyacrylic acid, mixtures and copolymers thereof. The polymers of the present invention may be natural or synthetic in origin, including gelatin, chitosan, dextrin, cyclodextrin, Poly(urethanes), Poly(siloxanes) or silicones, Poly(acrylates) such as poly(methyl methacrylate), poly(butyl methacrylate), and Poly(2-hydroxy ethyl methacrylate), Poly(vinyl alcohol) Poly(olefins) such as poly(ethylene), poly(isoprene), halogenated polymers such as Poly(tetrafluoroethylene)—and derivatives and copolymers such as those commonly sold as Teflon® products, Poly(vinylidine fluoride), Poly(vinyl acetate), Poly(vinyl pyrrolidone), Poly(acrylic acid), Polyacrylamide, Poly(ethylene-co-vinyl acetate), Poly(ethylene glycol), Poly(propylene glycol), Poly(methacrylic acid); etc. Suitable polymers also include absorbable and/or resorbable polymers including the following, combinations, copolymers and derivatives of the following: Polylactides (PLA), Polyglycolides (PGA), Poly(lactide-co-glycolides) (PLGA), Polyanhydrides, Polyorthoesters, Poly(N-(2-hydroxypropyl)methacrylamide), Poly(1-aspartamide), etc.

Having thus described the preferred embodiments of the present invention, those of skill in the art will be readily able to apply the teachings found herein to yet other embodiments without departing from the scope of the claims hereto attached.

Claims

1. A stent holder for removeably holding a stent during a coating process wherein the stent holder comprises a stent mounting portion comprising at least two arms upon which the stent is mounted, the at least two arms defining a hollow space therebetween, andan electrically chargeable section separate from the stent mounting portion,wherein the arms form an elliptical portion configured to exert force on an inner surface of the stent,wherein the arms are coupled to the electrically chargeable section that electrically charges the stent during the coating process and at least a portion of the electrically chargeable section includes a dimension larger than an inner diameter of the stent so that the stent sits on the electrically chargeable section, andwherein when the elliptical portion exerts force on the inner surface of the stent, the arms diverge from a central axis of the stent holder, making at least one bend, and converge at the central axis of the stent holder, or the arms diverge from a central axis of the stent holder and arc to converge at the central axis of the stent holder, the arms touching one another both where the arms diverge and where the arms converge.
2. The stent holder of claim 1, wherein the electrically chargeable section comprises at least one of a memory metal, or stainless steel.
3. The stent holder of claim 1, wherein the holder is disposable.
4. The stent holder of claim 1, wherein the holder comprises a mask for masking at least a part of the stent.
5. The stent holder of claim 4, wherein the mask comprises at least one of a polymer, a non-stick material, or a non-conducting material.
6. The stent holder of claim 1, wherein the holder comprises a support interfacing portion for interfacing with a support, wherein the support supports and electrically charges the support interfacing portion.
7. The stent holder of claim 1, wherein the stent slides over the elliptical portion of the stent holder.
8. The stent holder of claim 1, wherein the stent mounting portion has a collapsed and an expanded state, wherein the collapsed state reduces contact between the stent mounting portion and the stent during stent removal or stent placement on the stent mounting portion.
9. The stent holder of claim 8, wherein the stent mounting portion in the expanded state has an outer diameter approximately equal to the stent inner diameter for securely mounting the stent while minimizing stent deformation.
10. The stent holder of claim 9, wherein the stent mounting portion comprises a mask for masking at least a part of the stent.
11. The stent holder of claim 10, wherein the mask comprises at least one of a polymer, or a non-stick material.
12. The stent holder of claim 9, wherein the stent mounting portion comprises a spring section.
13. The holder of claim 1, wherein the holder further comprises a member for manipulating the electrical field around the stent.

CROSS-REFERENCE

This application claims the benefit of U.S. Provisional Application No. 60/862,592, filed Oct. 23, 2006, which application is incorporated herein by reference.

US Referenced Citations (361)

Number	Name	Date	Kind
3087660	Endicott	Apr 1963	A
3087860	Endicott	Apr 1963	A
3123077	Alcamo	Mar 1964	A
3457280	Schmitt et al.	Jul 1969	A
3597449	Deprospero et al.	Aug 1971	A
3929992	Sehgal et al.	Dec 1975	A
4000137	Dvonch et al.	Dec 1976	A
4285987	Ayer et al.	Aug 1981	A
4326532	Hammar	Apr 1982	A
4336381	Nagata et al.	Jun 1982	A
4582731	Smith	Apr 1986	A
4655771	Wallsten	Apr 1987	A
4733665	Palmaz	Mar 1988	A
4734227	Smith	Mar 1988	A
4734451	Smith	Mar 1988	A
4931037	Wetterman	Jun 1990	A
4950239	Gahara	Aug 1990	A
4985625	Hurst	Jan 1991	A
5000519	Moore	Mar 1991	A
5090419	Palestrant	Feb 1992	A
5096848	Kawamura	Mar 1992	A
5106650	Hoy et al.	Apr 1992	A
5158986	Cha et al.	Oct 1992	A
5195969	Wang et al.	Mar 1993	A
5243023	Dezern	Sep 1993	A
5270086	Hamlin	Dec 1993	A
5288711	Mitchell et al.	Feb 1994	A
5324049	Mistrater et al.	Jun 1994	A
5340614	Perman et al.	Aug 1994	A
5342621	Eury	Aug 1994	A
5350361	Tsukashima et al.	Sep 1994	A
5350627	Nemphos et al.	Sep 1994	A
5356433	Rowland et al.	Oct 1994	A
5366504	Andersen et al.	Nov 1994	A
5368045	Clement et al.	Nov 1994	A
5372676	Lowe	Dec 1994	A
5385776	Maxfield et al.	Jan 1995	A
5403347	Roby et al.	Apr 1995	A
5470603	Staniforth et al.	Nov 1995	A
5494620	Liu et al.	Feb 1996	A
5500180	Anderson et al.	Mar 1996	A
5556383	Wang et al.	Sep 1996	A
5562922	Lambert	Oct 1996	A
5569463	Helmus et al.	Oct 1996	A
5609629	Fearnot et al.	Mar 1997	A
5626611	Liu et al.	May 1997	A
5626862	Brem et al.	May 1997	A
5674242	Phan et al.	Oct 1997	A
5725570	Heath	Mar 1998	A
5800511	Mayer	Sep 1998	A
5811032	Kawai et al.	Sep 1998	A
5824049	Ragheb et al.	Oct 1998	A
5837313	Ding et al.	Nov 1998	A
5873904	Ragheb et al.	Feb 1999	A
5876426	Kume et al.	Mar 1999	A
5924631	Rodrigues et al.	Jul 1999	A
5948020	Yoon et al.	Sep 1999	A
5957975	Lafont et al.	Sep 1999	A
6013855	McPherson et al.	Jan 2000	A
6077880	Castillo et al.	Jun 2000	A
6129755	Mathis et al.	Oct 2000	A
6143037	Goldsten et al.	Nov 2000	A
6143314	Chandrashekar et al.	Nov 2000	A
6146356	Wang et al.	Nov 2000	A
6146404	Kim et al.	Nov 2000	A
6153252	Hossainy et al.	Nov 2000	A
6171327	Daniel et al.	Jan 2001	B1
6190699	Luzzi et al.	Feb 2001	B1
6206914	Soykan et al.	Mar 2001	B1
6231600	Zhong et al.	May 2001	B1
6245104	Alt	Jun 2001	B1
6248127	Shah et al.	Jun 2001	B1
6248129	Froix	Jun 2001	B1
6251980	Lan et al.	Jun 2001	B1
6273913	Wright et al.	Aug 2001	B1
6284758	Egi et al.	Sep 2001	B1
6309669	Setterstrom et al.	Oct 2001	B1
6319541	Pletcher et al.	Nov 2001	B1
6336934	Gilson et al.	Jan 2002	B1
6342062	Suon et al.	Jan 2002	B1
6355691	Goodman	Mar 2002	B1
6358556	Ding et al.	Mar 2002	B1
6361819	Tedeschi et al.	Mar 2002	B1
6364903	Tseng et al.	Apr 2002	B2
6368658	Schwarz et al.	Apr 2002	B1
6372246	Wei et al.	Apr 2002	B1
6387121	Alt	May 2002	B1
6409716	Sahatjian et al.	Jun 2002	B1
6414050	Howdle et al.	Jul 2002	B1
6416779	D-Augustine et al.	Jul 2002	B1
6448315	Lidgren et al.	Sep 2002	B1
6461644	Jackson et al.	Oct 2002	B1
6495163	Jordan	Dec 2002	B1
6497729	Moussy et al.	Dec 2002	B1
6506213	Mandel et al.	Jan 2003	B1
6517860	Rosser et al.	Feb 2003	B1
6521258	Mandel et al.	Feb 2003	B1
6524698	Schmoock	Feb 2003	B1
6537310	Palmaz et al.	Mar 2003	B1
6541033	Shah	Apr 2003	B1
6572813	Zhang et al.	Jun 2003	B1
6575933	Wittenberger et al.	Jun 2003	B1
6610013	Fenster et al.	Aug 2003	B1
6627246	Mehta et al.	Sep 2003	B2
6649627	Cecchi et al.	Nov 2003	B1
6660176	Tepper et al.	Dec 2003	B2
6669785	DeYoung et al.	Dec 2003	B2
6669980	Hanson et al.	Dec 2003	B2
6670407	Howdle et al.	Dec 2003	B2
6682757	Wright	Jan 2004	B1
6706283	Appel et al.	Mar 2004	B1
6710059	Labrie et al.	Mar 2004	B1
6720003	Chen et al.	Apr 2004	B2
6726712	Raeder-Devens et al.	Apr 2004	B1
6736996	Carbonell et al.	May 2004	B1
6743505	Antall et al.	Jun 2004	B2
6749902	Yonker et al.	Jun 2004	B2
6755871	Damaso et al.	Jun 2004	B2
6756084	Fulton et al.	Jun 2004	B2
6767558	Wang et al.	Jul 2004	B2
6780475	Fulton et al.	Aug 2004	B2
6800663	Asgarzadeh et al.	Oct 2004	B2
6815218	Jacobsen et al.	Nov 2004	B1
6821549	Jayaraman	Nov 2004	B2
6837611	Kuo et al.	Jan 2005	B2
6838089	Carlsson et al.	Jan 2005	B1
6838528	Zhou et al.	Jan 2005	B2
6858598	McKearn et al.	Feb 2005	B1
6860123	Uhlin et al.	Mar 2005	B1
6868123	Bellas et al.	Mar 2005	B2
6884377	Burnham et al.	Apr 2005	B1
6884823	Plerick et al.	Apr 2005	B1
6897205	Beckert et al.	May 2005	B2
6905555	DeYoung et al.	Jun 2005	B2
6908624	Hossainy et al.	Jun 2005	B2
6916800	McKearn et al.	Jul 2005	B2
6923979	Fotland et al.	Aug 2005	B2
6939569	Green et al.	Sep 2005	B1
6973718	Sheppard et al.	Dec 2005	B2
7148201	Stern et al.	Dec 2006	B2
7152452	Kokish	Dec 2006	B2
7160592	Rypacek et al.	Jan 2007	B2
7163715	Kramer	Jan 2007	B1
7169404	Hossainy et al.	Jan 2007	B2
7171255	Holupka et al.	Jan 2007	B2
7201750	Eggers et al.	Apr 2007	B1
7201940	Kramer	Apr 2007	B1
7229837	Chen	Jun 2007	B2
7278174	Villalobos	Oct 2007	B2
7279174	Pacetti et al.	Oct 2007	B2
7308748	Kokish	Dec 2007	B2
7326734	Zi et al.	Feb 2008	B2
7378105	Burke et al.	May 2008	B2
7419696	Berg et al.	Sep 2008	B2
7429378	Serhan et al.	Sep 2008	B2
7444162	Hassan	Oct 2008	B2
7455658	Wang	Nov 2008	B2
7455688	Furst et al.	Nov 2008	B2
7456151	Li et al.	Nov 2008	B2
7462593	Cuttitta et al.	Dec 2008	B2
7485113	Varner et al.	Feb 2009	B2
7524865	D'Amato et al.	Apr 2009	B2
7537610	Reiss	May 2009	B2
7537785	Loscalzo et al.	May 2009	B2
7553827	Attawia et al.	Jun 2009	B2
7713538	Lewis et al.	May 2010	B2
7727275	Betts et al.	Jun 2010	B2
7763277	Canham et al.	Jul 2010	B1
7837726	Von Oepen et al.	Nov 2010	B2
7919108	Rees et al.	Apr 2011	B2
7955383	Krivoruchko et al.	Jun 2011	B2
7972661	Pui et al.	Jul 2011	B2
20010026804	Boutignon	Oct 2001	A1
20010034336	Shah et al.	Oct 2001	A1
20010044629	Stinson	Nov 2001	A1
20010049551	Tseng et al.	Dec 2001	A1
20020007209	Scheerder et al.	Jan 2002	A1
20020051485	Bottomley	May 2002	A1
20020082680	Shanley et al.	Jun 2002	A1
20020091433	Ding et al.	Jul 2002	A1
20020099332	Slepian et al.	Jul 2002	A1
20020125860	Schworn et al.	Sep 2002	A1
20020133072	Wang et al.	Sep 2002	A1
20020144757	Craig et al.	Oct 2002	A1
20030001830	Wampler et al.	Jan 2003	A1
20030031699	Van Antwerp	Feb 2003	A1
20030077200	Craig et al.	Apr 2003	A1
20030088307	Shulze et al.	May 2003	A1
20030125800	Shulze et al.	Jul 2003	A1
20030143315	Pui et al.	Jul 2003	A1
20030170305	O'Neil et al.	Sep 2003	A1
20030180376	Dalal et al.	Sep 2003	A1
20030185964	Weber et al.	Oct 2003	A1
20030204238	Tedeschi	Oct 2003	A1
20030222017	Fulton et al.	Dec 2003	A1
20030222018	Yonker et al.	Dec 2003	A1
20030232014	Burke et al.	Dec 2003	A1
20040013792	Epstein et al.	Jan 2004	A1
20040018228	Fischell et al.	Jan 2004	A1
20040022853	Ashton et al.	Feb 2004	A1
20040044397	Stinson	Mar 2004	A1
20040059290	Palasis et al.	Mar 2004	A1
20040106982	Jalisi	Jun 2004	A1
20040122205	Nathan	Jun 2004	A1
20040126542	Fujiwara et al.	Jul 2004	A1
20040144317	Chuman et al.	Jul 2004	A1
20040157789	Geall	Aug 2004	A1
20040170685	Carpenter et al.	Sep 2004	A1
20040193177	Houghton et al.	Sep 2004	A1
20040193262	Shadduck	Sep 2004	A1
20040220660	Shanley et al.	Nov 2004	A1
20040224001	Pacetti et al.	Nov 2004	A1
20040236416	Falotico	Nov 2004	A1
20040260000	Chaiko	Dec 2004	A1
20050003074	Brown et al.	Jan 2005	A1
20050004661	Lewis et al.	Jan 2005	A1
20050010275	Sahatjian et al.	Jan 2005	A1
20050015046	Weber et al.	Jan 2005	A1
20050019747	Anderson et al.	Jan 2005	A1
20050038498	Dubrow et al.	Feb 2005	A1
20050048121	East et al.	Mar 2005	A1
20050049694	Neary	Mar 2005	A1
20050069630	Fox et al.	Mar 2005	A1
20050070990	Stinson	Mar 2005	A1
20050075714	Cheng et al.	Apr 2005	A1
20050079199	Heruth et al.	Apr 2005	A1
20050079274	Palasis et al.	Apr 2005	A1
20050084533	Howdle et al.	Apr 2005	A1
20050131513	Myers	Jun 2005	A1
20050147334	Kanazawa et al.	Jul 2005	A1
20050147734	Seppala et al.	Jul 2005	A1
20050166841	Robida	Aug 2005	A1
20050175772	Worsham et al.	Aug 2005	A1
20050177223	Palmaz	Aug 2005	A1
20050191491	Wang et al.	Sep 2005	A1
20050196424	Chappa	Sep 2005	A1
20050208102	Schultz	Sep 2005	A1
20050216075	Wang et al.	Sep 2005	A1
20050238829	Motherwell et al.	Oct 2005	A1
20050238839	Takagi et al.	Oct 2005	A1
20050255327	Chaney	Nov 2005	A1
20050260186	Bookbinder et al.	Nov 2005	A1
20050268573	Yan	Dec 2005	A1
20050288481	Desnoyer et al.	Dec 2005	A1
20060001011	Wilson et al.	Jan 2006	A1
20060020325	Burgermeister et al.	Jan 2006	A1
20060030652	Adams et al.	Feb 2006	A1
20060045901	Weber et al.	Mar 2006	A1
20060089705	Ding et al.	Apr 2006	A1
20060093771	Rypacek et al.	May 2006	A1
20060094744	Maryanoff et al.	May 2006	A1
20060116755	Stinson	Jun 2006	A1
20060121089	Michal et al.	Jun 2006	A1
20060134211	Lien et al.	Jun 2006	A1
20060136041	Schmid et al.	Jun 2006	A1
20060147611	Coye et al.	Jul 2006	A1
20060147698	Carroll et al.	Jul 2006	A1
20060153729	Stinson	Jul 2006	A1
20060160455	Sugyo et al.	Jul 2006	A1
20060188547	Bezwada	Aug 2006	A1
20060193886	Owens et al.	Aug 2006	A1
20060193890	Owens et al.	Aug 2006	A1
20060198868	DeWitt et al.	Sep 2006	A1
20060210638	Liversidge et al.	Sep 2006	A1
20060216324	Stucke et al.	Sep 2006	A1
20060222756	Davila et al.	Oct 2006	A1
20060228415	Oberegger et al.	Oct 2006	A1
20060276877	Owens et al.	Dec 2006	A1
20070009564	McClain et al.	Jan 2007	A1
20070032864	Furst et al.	Feb 2007	A1
20070038227	Massicotte et al.	Feb 2007	A1
20070059350	Kennedy et al.	Mar 2007	A1
20070110888	Radhakrishnan et al.	May 2007	A1
20070123973	Roth et al.	May 2007	A1
20070123977	Cottone et al.	May 2007	A1
20070128274	Zhu et al.	Jun 2007	A1
20070148251	Hossainy et al.	Jun 2007	A1
20070154554	Burgermeister et al.	Jul 2007	A1
20070196423	Ruane et al.	Aug 2007	A1
20070198081	Castro et al.	Aug 2007	A1
20070203569	Burgermeister et al.	Aug 2007	A1
20070259017	Francis	Nov 2007	A1
20070280992	Margaron et al.	Dec 2007	A1
20080051866	Chen et al.	Feb 2008	A1
20080071359	Thornton et al.	Mar 2008	A1
20080075753	Chappa	Mar 2008	A1
20080077232	Nishide	Mar 2008	A1
20080095919	McClain et al.	Apr 2008	A1
20080097575	Cottone	Apr 2008	A1
20080097591	Savage et al.	Apr 2008	A1
20080107702	Jennissen	May 2008	A1
20080118543	Pacetti et al.	May 2008	A1
20080124372	Hossainy et al.	May 2008	A1
20080138375	Yan et al.	Jun 2008	A1
20080206304	Lindquist et al.	Aug 2008	A1
20080213464	O'Connor	Sep 2008	A1
20080255510	Wang	Oct 2008	A1
20080269449	Chattopadhyay et al.	Oct 2008	A1
20080292776	Dias et al.	Nov 2008	A1
20080300669	Hossainy	Dec 2008	A1
20090043379	Prescott	Feb 2009	A1
20090062909	Taylor et al.	Mar 2009	A1
20090068266	Raheja et al.	Mar 2009	A1
20090076446	Dubuclet et al.	Mar 2009	A1
20090082855	Borges et al.	Mar 2009	A1
20090098178	Hofmann et al.	Apr 2009	A1
20090105809	Lee et al.	Apr 2009	A1
20090110711	Trollsas et al.	Apr 2009	A1
20090111787	Lim et al.	Apr 2009	A1
20090123515	Taylor et al.	May 2009	A1
20090186069	DeYoung et al.	Jul 2009	A1
20090202609	Keough et al.	Aug 2009	A1
20090216317	Cromack et al.	Aug 2009	A1
20090227949	Freyman et al.	Sep 2009	A1
20090231578	Ling et al.	Sep 2009	A1
20090263460	McDonald	Oct 2009	A1
20090285974	Kerrigan	Nov 2009	A1
20090292351	McClain et al.	Nov 2009	A1
20090297578	Trollsas et al.	Dec 2009	A1
20100015200	McClain et al.	Jan 2010	A1
20100030261	McClain et al.	Feb 2010	A1
20100042206	Yadav et al.	Feb 2010	A1
20100055145	Betts et al.	Mar 2010	A1
20100055294	Wang et al.	Mar 2010	A1
20100063570	Pacetti et al.	Mar 2010	A1
20100063580	McClain et al.	Mar 2010	A1
20100074934	Hunter	Mar 2010	A1
20100155496	Stark et al.	Jun 2010	A1
20100166869	Desai et al.	Jul 2010	A1
20100196482	Radovic-Moreno et al.	Aug 2010	A1
20100198330	Hossainy et al.	Aug 2010	A1
20100198331	Rapoza et al.	Aug 2010	A1
20100211164	McClain et al.	Aug 2010	A1
20100228348	McClain et al.	Sep 2010	A1
20100233332	Xing et al.	Sep 2010	A1
20100239635	McClain et al.	Sep 2010	A1
20100241220	McClain et al.	Sep 2010	A1
20100256746	Taylor et al.	Oct 2010	A1
20100256748	Taylor et al.	Oct 2010	A1
20100272778	McClain et al.	Oct 2010	A1
20100298928	McClain et al.	Nov 2010	A1
20110009953	Luk et al.	Jan 2011	A1
20110034422	Kannan et al.	Feb 2011	A1
20110159069	Shaw et al.	Jun 2011	A1
20110160751	Granja	Jun 2011	A1
20110190864	McClain et al.	Aug 2011	A1
20110238161	Fulton et al.	Sep 2011	A1
20110257732	McClain et al.	Oct 2011	A1
20110264190	McClain et al.	Oct 2011	A1
20110301697	Hoffmann et al.	Dec 2011	A1
20120064124	McClain et al.	Mar 2012	A1
20120064143	Sharp et al.	Mar 2012	A1
20120065723	Drasler et al.	Mar 2012	A1
20120101566	Mews et al.	Apr 2012	A1
20120150275	Shaw-Klein	Jun 2012	A1
20120172787	McClain et al.	Jul 2012	A1
20120177742	McClain et al.	Jul 2012	A1
20120271396	Zheng et al.	Oct 2012	A1
20120280432	Chen et al.	Nov 2012	A1
20120323311	McClain et al.	Dec 2012	A1
20130085515	To et al.	Apr 2013	A1

Foreign Referenced Citations (117)

Number	Date	Country
2589761	Dec 2004	CA
2615452	Jan 2007	CA
2650590	Nov 2007	CA
2679712	Jul 2008	CA
2684482	Oct 2008	CA
2721832	Dec 2009	CA
1465410	Jan 2004	CN
1575860	Feb 2005	CN
1649551	Aug 2005	CN
1684641	Oct 2005	CN
1756575	Apr 2006	CN
1946452	Apr 2007	CN
0604022	Jun 1994	EP
0982041	Mar 2000	EP
1195822	Apr 2002	EP
1325758	Jul 2003	EP
1454677	Sep 2004	EP
2197070	Jun 2010	EP
2293357	Mar 2011	EP
2293366	Mar 2011	EP
1994-098902	Apr 1994	JP
06218063	Aug 1994	JP
H09-056807	Mar 1997	JP
10005345	Jan 1998	JP
2003533492	Nov 2001	JP
2003-205037	Jul 2003	JP
2003-533286	Nov 2003	JP
2003533492	Nov 2003	JP
2003533493	Nov 2003	JP
2004512059	Apr 2004	JP
2004173770	Jun 2004	JP
2004-518458	Jun 2004	JP
2004-529674	Sep 2004	JP
2005-505318	Feb 2005	JP
2005-523119	Aug 2005	JP
2005-5233332	Aug 2005	JP
2005-296690	Oct 2005	JP
2006506191	Feb 2006	JP
2007502281	Feb 2007	JP
2009-501566	Jan 2009	JP
2009525768	Jul 2009	JP
WO-2011-009096	Jan 1920	WO
WO-9506487	Mar 1995	WO
WO 9620698	Jul 1996	WO
WO 9745502	Dec 1997	WO
WO-0154662	Aug 2001	WO
WO-01-87371	Nov 2001	WO
WO-0187372	Nov 2001	WO
WO-0240702	May 2002	WO
WO-0243799	Jun 2002	WO
02074194	Sep 2002	WO
WO-02090085	Nov 2002	WO
WO-03039553	May 2003	WO
03082368	Oct 2003	WO
WO-03101624	Dec 2003	WO
2004009145	Jan 2004	WO
WO-2004028589	Apr 2004	WO
WO-2004043506	May 2004	WO
WO-2004045450	Jun 2004	WO
WO-2004098574	Nov 2004	WO
WO-2005-042623	May 2005	WO
WO-2005063319	Jul 2005	WO
WO-2005069889	Aug 2005	WO
WO-2005-117942	Dec 2005	WO
WO-2006014534	Feb 2006	WO
WO-2006052575	May 2006	WO
WO-2006065685	Jun 2006	WO
WO-2006-083796	Aug 2006	WO
WO-2006-099276	Sep 2006	WO
WO-2007-002238	Jan 2007	WO
WO-2007-011707	Jan 2007	WO
WO-2007-011707	Jan 2007	WO
WO-2007-011708	Jan 2007	WO
WO-2007-011708	Jan 2007	WO
WO-2007-127363	Jan 2007	WO
WO-2007092179	Aug 2007	WO
WO 2007143609	Dec 2007	WO
WO-2008042909	Apr 2008	WO
WO-2008-046641	Apr 2008	WO
WO-2008-046642	Apr 2008	WO
WO-2008052000	May 2008	WO
WO-2008070996	Jun 2008	WO
WO 2008086369	Jul 2008	WO
WO-2008-131131	Oct 2008	WO
WO-2008148013	Dec 2008	WO
2009051614	Apr 2009	WO
WO-2009051780	Apr 2009	WO
WO-2009146209	Dec 2009	WO
WO 2010009335	Jan 2010	WO
WO-2010075590	Jul 2010	WO
WO-2010-111196	Sep 2010	WO
WO-2010-111196	Sep 2010	WO
WO-2010-111232	Sep 2010	WO
WO-2010-111232	Sep 2010	WO
WO-2010-111238	Sep 2010	WO
WO-2010-111238	Sep 2010	WO
WO-2010-120552	Oct 2010	WO
WO-2010-120552	Oct 2010	WO
WO-2010-121187	Oct 2010	WO
WO-2010-121187	Oct 2010	WO
2010136604	Dec 2010	WO
WO-2011097103	Aug 2011	WO
WO-2011119762	Sep 2011	WO
WO-2011130448	Oct 2011	WO
WO-2011133655	Oct 2011	WO
WO-2012009684	Jan 2012	WO
WO-2012034079	Mar 2012	WO
WO-2012082502	Jun 2012	WO
WO-2012092504	Jul 2012	WO
WO-2012142319	Oct 2012	WO
WO-2012166819	Dec 2012	WO
WO-2013012689	Jan 2013	WO
WO-2013025535	Feb 2013	WO
WO-2013059509	Apr 2013	WO
WO-2013173657	Nov 2013	WO
WO-2013177211	Nov 2013	WO
WO-2014063111	Apr 2014	WO

Non-Patent Literature Citations (363)

Entry
PCT/US07/10227 Search Report mailed Aug. 8, 2008.
PCT/US2011/032371, International Search Report dated Jul. 7, 2011.
PCT/US09/41045 Search Report dated Aug. 11, 2009.
PCT/US08/11852 Search Report dated Dec. 19, 2008.
PCT/US08/64732 Search Report dated Sep. 4, 2008.
PCT/US08/60671 Search Report dated Sep. 5, 2008.
PCT/US08/50536 Search Report dated Jun. 2, 2008.
PCT/US07/80213 Search Report dated Apr. 16, 2008.
PCT/US09/50883 Search Report dated Nov. 17, 2009.
PCT/US07/82275 Search Report mailed Apr. 18, 2008.
PCT/US06/27322 Search Report mailed Apr. 25, 2007.
PCT/US06/27321 Search Report mailed Oct. 16, 2007.
PCT/US06/24221 Search Report mailed Jan. 29, 2007.
McAlpine, J.B. et al., “Revised NMR Assignments for Rapamycin,” J. Antibiotics 44:688-690 (1991).
Ong and Serruys, “Technology Insight: an overview of research in drug-eluting stents,” Nat. Clin. Parct. Cardiovas. Med. 2(12):647 (2005).
Latella et al., “Nanoindentation hardness. Young's modulus, and creep behavior of organic-inorganic silica-based sol-gel thin films on copper,” J Mater Res 23(9): 2357-2365 (2008).
Schmidt et al., “A Comparison of the Mechanical Performance Characteristics of Seven Drug-Eluting Stent Systems,” Catheterization and Cardiovascular Interventions 73:350-360 (2009).
Schmidt et al., “In vitro measurement of quality parameters of stent-catheter systems,” Biomed Techn 50(S1):1505-1506 (2005).
Schmidt et al., “New aspects of in vitro testing of arterial stents based on the new European standard,” EN 14299, [online] (2009), [retrieved on Mar. 3, 2001] http://www.lib0ev.de/p1/pdf/EN14299.pdf (2009).
Szabadits et al., “Flexibility and trackability of laser cut coronary stent systems,” Acta of Bioengineering and Biomechanics 11(3):11-18 (2009).
PCT/US10/42355 Search Report mailed Sep. 2, 2010.
PCT/US10/28265 Search Report and Written Opinion mailed Dec. 13, 2010.
U.S. Appl. No. 11/158,724 Office Action Mailed Sep. 17, 2009.
Akoh et al., “One-Stage Synthesis of Raffinose Fatty Acid Polyesters.” Journal Food Science (1987) 52:1570.
Albert et al., “Antibiotics for preventing recurrent urinary tract infection in non-pregnant women,” Cochrane Database System Rev. 3, CD001209 (2004).
Au et al., “Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial,” Journal of the National Cancer Institute, 93(8), 597-604 (2001).
AU2007243268 Exam Report dated Aug. 31, 2011.
AU2009251504 Exam Report dated Dec. 8, 2011.
AU2009270849 Exam Report dated Feb. 14, 2012.
Balss et al., “Quantitative spatial distribution of sirolumus and polymers in drug-eluting stents using confocal Raman microscopy,” J. of Biomedical Materials Research Part A, 258-270 (2007).
Belu et al., “Three-Dimensional Compositional Analysis of Drug Eluting Stent Coatings Using Cluster Secondary Ioan Mass Spectroscopy,” Anal. Chem. 80:624-632 (2008).
Belu, et al., “Chemical imaging of drug eluting coatings: Combining surface analysis and confocal Rama microscopy” J. Controlled Release 126: 111-121 (2008).
Boneff, “Topical Treatment of Chronic Prostatitis and Premature Ejaculation,” International Urology and Nephrology 4(2):183-186 (1971).
Bookbinder et al., “A recombinant human enzyme for enhanced interstitial transport of therapeutics,” Journal of Controlled Release 114:230-241 (2006).
Borchert et al., “Prevention and treatement of urinary tract infection with probiotics: Review and research perspective,” Indian Journal Urol. 24(2):139-144 (2008).
Brunstein et al., “Histamine, a vasoactive agent with vascular disrupting potential improves tumour response by enhancing local drug delivery,” British Journal of Cancer 95:1663-1669 (2006).
Bugay et al., “Raman Analysis of Pharmaceuticals,” in “Applications of Vibrational Spectroscopy in Pharmaceutical Research and Development,” Ed. Pivonka, D.E., Chalmers, J.M., Griffiths, P.R. (2007) Wiley and Sons.
CA 2615452 Office Action dated Dec. 19, 2012.
CA 2684482 Office Action Jul. 11, 2012.
CA 2684482 Office Action dated Nov. 10, 2011.
CA 2688314 Office Action dated Jun. 6, 2012.
CA 2730995 Office Action dated Sep. 26, 2012.
CA 2757276 Office Action dated Feb. 15, 2013.
CA 2756307 Office action dated Feb. 18, 2013.
CA 2756386 Office action dated Mar. 15, 2013.
CA 2613280 Office Action dated Oct. 2, 2012.
Cadieux et al., “Use of triclosan-eluting ureteral stents in patients with long-term stents,” J. Endourol (Epub) (Jun. 19, 2009).
Channon et al., “Nitric Oxide Synthase in Atherosclerosis and Vascular Injury: Insights from Experimental Gene Therapy,” Arteriosclerosis, Thrombosis and Vascular Biology, 20(8):1873-1881 (2000).
Chen et al. Immobilization of heparin on a silicone surface through a heterobifunctional PEG spacer. Biomaterials. Dec. 2005;26(35):7418-24.
Clair and Burks, “Thermoplastic/Melt-Processable Polyimides,” NASA Conf. Pub. #2334 (1984), pp. 337-355.
CN 2006800258093 Office Action dated May 30, 2012.
CN 200880007308.1 Office Action dated Nov. 23, 2011.
CN 200880007308.1 Office Action dated Oct. 18, 2012.
CN 200880020515 Office Action dated Oct. 9, 2012.
CN 200880100102.3 Office Action dated Jun. 1, 2012.
CN 200980122691 Office Action dated Oct. 10, 2012.
CN 200780047425.6 Office action dated Aug. 3, 2012.
CN 200780047425.6 Office action dated Feb. 28, 2013.
CN 200980136432.2 Office action dated Jan. 14, 2013.
CRC Handbook of chemistry and physics. 71st ed. David R. Lide, Editor-in-Chief. Boca Raton, FL, CRC Press; 1990; 6-140.
Cyrus et al., “Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury,” Arterioscler Thromb Vase Biol 2008;28:820-826.
DERWENT-ACC-No. 2004-108578 Abstracting 2004003077; Jan. 8, 2004; 3 pages.
DiStasi et al., “Percutaneous sequential bacillus Calmette-Guerin and mitomycin C for panurothelial carcinomatosis,” Can. J. Urol. 12(6):2895-2898 (2005).
Domb and Langer, “Polyanhydrides. I. Preparation of High Molecular Weight Polyanhydrides. ”J. Polym Sci. 25:3373-3386 (1987).
Dzik-Jurasz, “Molecular imaging in vivo: an introduction,” The British Journal of Radiology, 76:S98-S109 (2003).
EA 201001497 Office Action dated Feb. 11, 2013.
EA 200901254/28 Office Action dated Jul. 18, 2012.
Electrostatic Process, Wiley Encyclopedia of Electrical and Electronics Engineering, John Wiley & Sons, Inc. 1999; 7:15-39.
Eltze et al., “Imidazoquinolinon, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly (ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors,” Mol. Pharmacol 74(6):1587-1598 (2008).
EP06773731.2 Search Report dated Oct. 2, 2012.
EP06787258.0 Search Report dated Feb. 6, 2012.
EP07756094.4 Search Report dated Aug. 31, 2012.
EP08733210.2 Search Report dated Oct. 23, 2012.
EP08756215.3 Search Report dated Oct. 5, 2011.
EP08756215.3 Search Report dated Jan. 28, 2013.
EP09805981.9 Office Action dated Feb. 13, 2013.
EP06787258.0 Office Action dated Mar. 15, 2013.
EP09755571.8 Search Report dated Apr. 9, 2013.
EP08705772.5 Search Report dated Feb. 20, 2013.
Ettmayer et al. Lessons learned from marketed and investigational prodrugs. J Med Chem. May 6, 2004;47(10):2393-404.
Fibbi et al., “Chronic inflammation in the pathogenesis of benign prostatic hyperplasia,” Int J Androl. Jun. 1, 2010;33(3):475-88.
Fleischmann et al., “High Expression of Gastrin-Releasing Peptide Receptors in the Vascular bed of Urinary Tract Cancers: Promising Candidates for Vascular Targeting Applications.” Jun. 2009, Endocr. Relat. Cancer 16(2):623-33.
Froehlich et al., “Conscious sedation for gastroscopy: patient tolerance and cardiorespiratory parameters,” Gastroenterology 108(3):697-704 (1995).
Fujiwara et al., “Insulin-like growth factor 1 treatment via hydrogels rescues cochlear hair cells from ischemic injury,” Oct. 29, 2008, NeuroReport 19(16):1585-1588.
Fulton et al. Thin Fluoropolymer films and nanoparticle coatings from the rapid expansion of supercritical carbon dioxide solutions with electrostatic collection, Polymer Communication. 2003; 2627-3632.
Green et al., “Simple conjugated polymer nanoparticles as biological labels,” Proc Roy Soc A. published online Jun. 24, 2009 doi:10.1098/rspa.2009.0181.
Griebenow et al., “On Protein Denaturation in Aqueous-Organic Mixtures but not in Pure Organic Solvents,” J. Am Chem Soc., vol. 118. No. 47, 11695-11700 (1996).
Hamilos et al., “Differential effects of Drug-Eluting Stents on Local Endothelium-Dependent Coronary Vasomotion.” JACC vol. 51, No. 22, 2008, Endothelium and DES Jun. 3, 2008:2123-9.
Hartmann et al., “Tubo-ovarian abscess in virginal adolescents: exposure of the underlying etiology,” J. Pediatr Adolesc Gynecol, 22(3):313-16 (2009).
Hasegawa et al., “Nylong 6/Na-montmorillonite nanocomposites prepared by compounding Nylon 6 with Na-montmorillonite slurry,” Polymer 44 (2003) 2933-2937.
Hinds, WC. Aerosol Technology, Properties, Behavior and Measurement of Airborne Particles, Deparment of Environmental Health Sciences, Harvard University School of Public Health, Boston, Massachusetts. 1982; 283-314.
Hladik et al., “Can a topical microbicide prevent rectal HIV transmission?” PLoS Med. 5(8):e167 (2008).
Iconomidou et al., “Secondary Structure of Chorion Proteins of the Teleosatan Fish Dentex dentex by ATR FF-IR and FT-Raman Spectroscopy,” J. of Structural Biology, 132, 112-122 (2000).
Jackson et al., “Characterization of perivascular poly(lactic-co-glycolic acid) films containing paclitaxel” Int. J. of Pharmaceutics, 283:97-109 (2004), incorporated in its entirety herein by reference.
Jensen et al., Neointimal hyperplasia after sirollmus-eluting and paclitaxel-eluting stend implantation in diabetic patients: the randomized diabetes and drug eluting stent (DiabeDES) intravascular ultrasound trial. European heart journal (29), pp. 2733-2741. Oct. 2, 2008. Retrieved from the Internet. Retrieved on [Jul. 17, 2012]. URL:<http://curhcartj.oxfordjournals.org/content/29/22/2733.full.pdf> entire document.
Jewell, et al., “Release of Plasmid DNA from Intravascular Stents Coated with Ultrathin Multilayered Polyelectrolyte Films” Biomacromolecules. 7: 2483-2491 (2006).
Johns, H.E, J.R.Cunningham, Thomas, Charles C., Publisher, “The Physics of Radiology,” 1983, Springfield, IL, pp. 133-143.
Joner et al. “Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma,” Arterioscler Thromb Vase Biol. 2008;28:1960-1966.
Mei et al., “Local Delivery of Modified Paclitaxel-Loaded Poly( ε-caprolactone)/Pluronic F68 Nanoparticles for Long-Term Inhibition of Hyperplasia,” Journal of Pharmaceutical Sciences, vol. 98, No. 6, Jun. 2009.
Jovanovic et al. “Stabilization of Proteins in Dry Powder Formulations Using Supercritical Fluid Technology,” Pharm. Res. 2004; 21(11).
JP 2008-521633 Office Action dated Oct. 12, 2012.
JP2008-521633 Office Action dated Dec. 28, 2011.
JP-2009-534823 Office Action dated Sep. 20, 2012.
JP-2009-534823 Office Action dated Feb. 21, 2012.
JP-2009-545647 Office Action dated Jun. 5, 2012.
JP-2010-504253 Office Action dated Dec. 12, 2011.
JP-2010-504253 Office Action dated Dec. 7, 2012.
JP-2011-518920 Office action dated Dec. 17, 2012.
JP-2012-503677 Office action dated Jan. 18, 2013.
Kazemi et al., “The effect of betamethasone gel in reducing sore throat, cough, and hoarseness after laryngo-tracheal intubation,” Middle East J. Anesthesiol. 19(1):197-204 (2007).
Kehinde et al., “Bacteriology of urinary tract infection associated with indwelling J ureteral stents,” J. Endourol. 18(9):891-896 (2004).
Kelly et al., “Double-balloon trapping technique for embolization of a large wide-necked superior cerebellar artery aneurysm: case report,” Neurosurgery 63(4 Suppl 2):291-292 (2008).
Khan et al., Cyclic Acetals of4,1′,6′,-Trichloro-4,1′,6′,-Trideoxy-Trideoxy-galacto-Sucrose and their Conversion into Methyl Ether Derivatives. Carb. ResCarb. Res. (1990) 198:275-283.
Khan et al., “Chemistry and the new uses of Sucrose: How Important?” Pur and Appl. Chem (1984) 56:833-844.
Khan et al., “Enzymic Regioselective Hydrolysis of Peracetylated Reducing Disaccharides, Specifically at the Anomeric Centre: Intermediates for the Synthesis of Oligosaccharides.” Tetrahedron Letters (1933) 34:7767.
KR10-2008-7003756 Office Action dated Oct. 30, 2012.
Kurt et al., “Tandem oral, rectal and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability,” Am J. Emerg. Med. 27(5):631, e1-2 (2009).
Labhasetwar et al., “Arterial uptake of biodegradable nanoparticles: effect of surface modifications,” Journal of Pharmaceutical Sciences, vol. 87, No. 10, Oct. 1998; 1229-1234.
Lamm et al., “Bladder Cancer: Current Optimal Intravesical Treatment: Pharmacologic Treatment,” Urologic Nursing 25(5):323-6, 331-2 (Oct. 26, 2005).
Lee et al., “Novel therapy for hearing loss: delivery of insulin-like growth factor 1 to the cochlea using gelatin hydrogel,” Otol. Neurotol. 28(7):976-81 (2007).
Lehmann et al, “Drug treatment of nonviral sexually transmitted diseases: specific issues in adolescents,” Pediatr Drugs 3(7):481-494 (2001.
Mahoney et al., “Three-Dimensional Compositional Analysis of Drug Eluting Stent Coatings Using Cluster Secondary Ion mass Spectrometry,” Anal. Chem. , 80, 624-632 (2008).
Mario, C.D. et al., “Drug-Eluting Bioabsorbable Magnesium Stent,” J. Interventional Cardiology 16(6):391-395 (2004).
McAlpine, J.B. et al., “Revised NMR Assignments for Rapamycine,” J. Antibiotics 44:688-690 (1991).
Mehik et al., “Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospecitve, randomized, double-blind, placebo-controlled, pilot study,” Urology 62(3):425-429 (2003).
Melonakos et al., Treatment of low-grade bulbar transitional cell carcinoma with urethral instillation of mitomycin C, Oct. 28, 2008, Adv. Urol., 173694 Epub.
Merrett et al., “Interaction of corneal cells with transforming growth factor beta2-modified poly dimethyl siloxane surfaces,” Journal of Biomedical Materials Research, Part A, vol. 67 A, No. 3, pp. 981-993 (2003).
Middleton and Tipton, Synthetic biodegradable polymers as orthopedic devises. Biomaterials 2000; 21:2335-46.
Minchin, “Nanomedicine: sizing up targets with nanoparticles,” Nature Nanotechnology, vol. 33, Jan. 2008, 12-13.
Minoque et al., “Laryngotracheal topicalization with lidocaine before intubation decreases the incidence of coughing on emergence from general anesthesia,” Anesth. Analg. 99(4):1253-1257 (2004).
Mishima et al. “Microencapsulation of Proteins by Rapid Expansion of Supercritical Solution with a Nonsolvent,” AIChE J. 2000;46(4):857-65.
Mocco et al., “Pharos neurovascular intracranail stent: Elective use for a symptomatic stenosis refractory to medical therapy,” Catheter Cardiovasc. Interv. (epub) (Mar. 2009).
Mollen et al., “Prevalence of tubo-ovarian abcess in adolescents diagnosed with pelvice inflammatory disease in a pediatric emergency department,” Pediatr. Emerg. Care, 22(9): 621-625 (2006).
Moroni et at., “Post-ischemic brain damage:targeting PARP-1 within the ischemic neurovaschular units as a realistic avenue to stroke treatment,” FEBS J. 276(1):36-45 (2009).
Muhlen et al., “Magnetic Resonance Imaging Contrast Agent Targeted Toward Activated Platelets Allows in Vivo Detection of Thrombosis and Monitoring of Thrombolysis Circulation,” 118:258-267 (2008).
PCT/US08/50536 International Search Report mailed Jun. 2, 2008.
PCT/US08/60671 International Search Report mailed Sep. 5, 2008.
PCT/US08/64732 International Search Report mailed Sep. 4, 2008.
PCT/US09/41045 International Search Report mailed Aug. 11, 2009.
PCT/US09/50883 International Search Report mailed Nov. 17, 2009.
PCT/US12/46545 International Search Report mailed Nov. 20, 2012.
PCT/US12/50408 International Search Report mailed Oct. 19, 2012.
PCT/US2012/040040 International Search Report mailed Sep. 7, 2012.
Perry et al., Chemical Engineer's Handbook, 5th Edition, McGraw-Hill, New York, 1973; 20-106.
Torchlin, “Micellar Nanocarriers: Pharmaecutial Perspectives,” Pharmaceutical Research, vol. 24, No. 1, Jan. 2007.
Plas et al., “Tubers and tumors: rapamycin therapy for benign and malignant tumors”, Curr Opin Cell Bio 21: 230-236, (2009).
Poling et al., The Properties of Gases and Liquids. McGraw-Hill. 2001; 9:1-9.97.
Pontari, “Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment,” Drugs Aging 20(15):1111-1115 (2003).
Pontari, “Inflammation and anti-inflammatory therapy in chronic prostatits,” Urology 60(6Suppl):29-33 (2002).
Raganath et al., “Hydrogel matrix entrapping PLGA-paclitaxel microspheres: drug delivery with near zero-order release and implantability advantages for malignant brain tumour,” Pharm Res (Epub) Jun. 20, 2009).
Ranade et al., “Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent,” J. Biomed Mater. Res. 71(4):625-634 (2004).
Reddy et al., “Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery,” Circ Cardiovasc Interv 2008;1;209-216.
Sahajanand Medical Technologies (Supralimus Core; Jul. 6, 2008).
Schetsky, L. McDonald, “Shape Memory Alloys”, Encyclopedia of Chemical Technology (3d Ed), John Wiley & Sons 1982, vol. 20 pp. 726-736.
Schmidt et al., “New aspects of in vitro testing of arterial stents based on the new European standard,” EN 14299, [online] (2009), [retrieved on Mar. 10, 2010] http://www.lib0cv.de/pl/pdf/EN14299.pdf (2009).
Schmidt et al., “Trackability, Crossability, and Pushability of Coronary Stent Systems—An Experimental Approach,” Biomed Techn 47 (2002), Erg. 1, S. 124-126.
Schreiber, S.L. et al., “Atomic Structure of the Rapamycin Human Immunophilin FKBP-12 Complex,” J. Am. Chem. Soc. 113:7433-7435 (1991).
Sen et al., “Topical heparin: A promising agent for the prevention of tracheal stenosis in airway surgery,” J. Surg. Res (Epub ahead of print) Feb. 21, 2009.
Serruys, Patrick et al., Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel Disease, N. Engl. J. Med., 2001, vol. 344, No. 15, pp. 1117-1124.
SG201007602-4 Examination Report dated Feb. 13, 2013.
Simpson et al., “Hyaluronan and hyaluronidase in genitourinary tumors.” Front Biosci. 13:5664-5680.
Smith et al., “Mitomycin C and the endoscopic treatment of laryngotracheal stenosis: are two applications better than one?” Laryngoscope 119(2):272-283 (2009).
Szabadits et al., “Flexibility and trackability of laser cut coronary stent systems,” Acta of Bioengineering and Biomechanics 11(3): 11-18 (2009).
Thalmann et al., “Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery,” J Urol. 168(4 Pt 1):1381-1385 (2002).
Merriam-Webster Online Dictionary, obtained onlie at: http://www.merriam-webster.com/dictionary/derivative, downloaded 07 Jul. 5, 2008.
U.S. Appl. No. 11/158,724 Office Action Mailed Sep. 8, 2008.
U.S. Appl. No. 11/995,685 Office Action Mailed Aug. 20, 2010.
U.S. Appl. No. 11/995,685 Office Action Mailed Nov. 24, 2009.
U.S. Appl. No. 11/995,687 Office Action Mailed Sep. 28, 2011.
U.S. Appl. No. 12,298,459 Office Action Mailed Aug. 10, 2011.
U.S. Appl. No. 12/298,459 Office Action mailed Apr. 6, 2012.
U.S. Appl. No. 12/426,198 Office Action Mailed Feb. 6, 2012.
U.S. Appl. No. 12/426,198 Office Action Mailed Mar. 23, 2011.
U.S. Appl. No. 12/443,959 Office Action Mailed Dec. 13, 2012.
U.S. Appl. No. 12/443,959 Office Action mailed Feb. 15, 2012.
U.S. Appl. No. 12/504,597 Final Office Action Mailed Oct. 3, 2012.
U.S. Appl. No. 12/504,597 Office Action Mailed Dec. 5, 2011.
U.S. Appl. No. 12/522,379 Office Action Mailed Dec. 26, 2012.
U.S. Appl. No. 12/595,848 Office Action Mailed Jan. 13, 2012.
U.S. Appl. No. 12/601,101 Office Action Mailed Dec. 27, 2012.
U.S. Appl. No. 12/601,101 Office Action Mailed Mar. 27, 2012.
U.S. Appl. No. 12/648,106 Final Office Action Mailed Sep. 25, 2012.
U.S. Appl. No. 12/648,106 Office Action Mailed Jan. 30, 2012.
U.S. Appl. No. 12/729,156 Final Office Action Mailed Oct. 16, 2012.
U.S. Appl. No. 12/729,156 Office Action Mailed Feb. 1, 2012.
U.S. Appl. No. 12/729,580 Office Action Mailed Apr. 10, 2012.
U.S. Appl. No. 12/729,580 Office Action Mailed Jan. 22, 2013.
U.S. Appl. No. 12/729,603 Final Office Action Mailed Oct. 10, 2012.
U.S. Appl. No. 12/729,603 Office Action Mailed Mar. 27, 2012.
U.S. Appl. No. 12/751,902 Office Action Mailed Jul. 13, 2012.
U.S. Appl. No. 12/595,848 Office Action Mailed Mar. 15, 2013.
U.S. Appl. No. 12/738,411 Final Office action Mailed Apr. 11, 2013.
U.S. Appl. No. 12/762,007 Office action Mailed Feb. 11, 2013.
Unger et al., “Poly(ethylene carbonate): A thermoelastic and biodegradable biomaterial for drug eluting stent coatings?” Journal fo Controlled Release, vol. 117, Issue 3, 312-321 (2007).
Verma et al., “Effect of surface properties on nanoparticle-cell interactions,” Small 2010, 6, No. 1, 12-21.
Wagenlehner et al., “A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome: a multicentre, randomized, prospective, double-blind, placebo-controlled phase 3 study,” Eur Urol 9 (Epub) (Jun. 3, 2009).
Wang et al. Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials 2000; 27:5588-95.
Wang et al., “Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury,” Exp. Neurol 213(1):171-175 (2008).
Warner et al., “Mitomycin C and airway surgery: how well does it work?” Ontolaryngol Head Neck Surg. 138(6):700-709 (2008).
Wermuth, CG Similarity in drugs: reflections on analogue design. Drug Discov Today. Apr. 2006;11(7-8):348-54.
Witjes et al., “Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results,” Eur. Urol. 53(1):45-52.
PCT/US10/28253 Search Report and Written Opinion mailed Dec. 6, 2010.
PCT/US10/28265 Search Report and Written Opinion mailed Dec. 3, 2010.
PCT/US10/28195 Search Report and Written Opinion mailed Jan. 21, 2011.
PCT/US10/31470 Search Report and Written Opinion mailed Jan. 28, 2011.
PCT/US10/29494 Search Report and Written Opinion mailed Feb. 7, 2011.
PCT/US11/22623 Search Report and Written Opinion mailed Mar. 28, 2011.
PCT/US2011/044263 International Search Report, International Preliminary Report on Patentability and Written Opinion dated Feb. 9, 2012.
PCT/US2007/82775 International Preliminary Report on Patentablity dated Apr. 28, 2009.
PCT/US09/69603 International Search Report mailed Nov. 5, 2010.
PCT/US09/50883 International Preliminary Report on Patentability dated Jan. 18, 2011.
PCT/US10/28253 International Preliminary Report on Patentability dated Sep. 27, 2011.
PCT/US12/33367 International Search Report mailed Aug. 1, 2012.
PCT/US10/42355 International Preliminary Report on Patentability dated Jan. 17, 2012.
PCT/US2011/67921 Search Report and Written Opinion mailed Jun. 22, 2012.
PCT/US2011/051092 International Preliminary Report on Patentability dated Mar. 21, 2013.
PCT/US10/28195 International Preliminary Report on Patentability dated Oct. 6, 2011.
AU2006270221 Exam Report dated Apr. 6, 2010.
AU2011232760 Exam Report dated Apr. 10, 2013.
AU2012203203 Exam Report dated Apr. 12, 2013.
AU2007243268 Exam Report dated May. 15, 2013.
AU2012203577 Exam Report dated Jun. 7, 2013.
AU2011256902 Exam Report dated Jun. 13, 2013.
CA 2759015 Office action dated Apr. 8, 2013.
CA 2756388 Office Action dated Apr. 11, 2013.
CA 2730995 Office action dated May 29, 2013.
CA 2650590 Office action dated Jul. 23, 2013.
Chlopek et al. “The influence of carbon fibres on the resorption time and mechanical properties of the lactide-glycolide co-polymer.” J. Biomater. Sci. Polymer Edn, vol. 18, No. 11, pp. 1355-1368 (2007).
CN 200880100102.3 Office Action dated Apr. 11, 2013.
CN 200880007308.1 Office Action dated Jul. 3, 2013.
CN 200880020515 Office Action dated Jul. 22, 2013.
Cohen, et al. “Sintering Technique for the Preparation of Polymer Matrices fro the Controlled Release of Macromolecules.” Journal of Pharmaceutical Sciences, vol. 73, No. 8, 1984, p. 1034-1037.
Domingo, C. et al., “Precipication of ultrafine organic crystals from the rapid expansion of supercritical solutions over a capillary and a frit nozzle,” J. Supercritical Fluids 10:39-55 (1997).
EP07756094.4 Office action dated May 29, 2013.
EP08733210.2 Office action dated Jul. 16, 2013.
EP11769546.0 Search Report dated Sep. 19, 2013.
IN-368/DELNP/2008 Exam Report dated Oct. 17, 2011.
IL-208648 Official Notification dated Feb. 9, 2012.
JP-2009-534823 Office Action dated Apr. 23, 2013.
JP-2011-505248 Office action dated Jun. 4, 2013.
JP-2010-510441 Office action dated May 7, 2013.
JP-2009-545647 Office Action dated May 14, 2013.
Koh et al. “A novel nanostructured poly(lactic-co-glycolic-acid)-multi-walled carbon nantube composite for blood-contacting applications: Thrombogenicity studies.” Acta Biomaterialia 5 (2009): 3411-3422.
KR10-2008-7003756 Office Action dated Sep. 23, 2013.
NZ 588549 Examination Report dated Mar. 28, 2011.
Schmidt et al., “A Comparison of the Mechanical Performance Characteristics of Seven Drug-Eluting Stent Systems,” Catheterization and Cariovascular Interventions 73:350-360 (2009).
Shekunov et al. “Crystallization Processes in Pharmaceutical Technology and Drug Delivery Design.” Journal of Crystal Growth 211 (2000), pp. 122-136.
U.S. Appl. No 13/605,904 Office Action Mailed Nov. 27, 2012.
U.S. Appl. No. 13/384,216 Office action Mailed Apr. 24, 2013.
U.S. Appl. No. 13/340,472 Office action Mailed Apr. 26, 2013.
U.S. Appl. No. 12/729,156 Office action Mailed May 8, 2013.
U.S. Appl. No. 13/014,632 Office action Mailed May 8, 2013.
U.S. Appl. No. 13/086,335 Office action Mailed May 22, 2013.
U.S. Appl. No. 11/158/724 Office action Mailed May 23, 2013.
U.S. Appl. No. 12/601,101 Office action May 22, 2013.
U.S. Appl. No. 12/298,459 Office Action Mailed May 31, 2013.
U.S. Appl. No. 13/229,473 Office Action Mailed Jun. 17, 2013.
U.S. Appl. No. 13/605,904 Office Action Mailed Jun. 28, 2013.
U.S. Appl. No. 11/877,591 Office Action Mailed Jul. 1, 2013.
U.S. Appl. No. 12/748,134 Office Action Mailed Jul. 18, 2013.
U.S. Appl. No. 12/738,411 Office action Mailed Aug. 21, 2013.
U.S. Appl. No. 12/522,379 Final Office Action Mailed Aug. 28, 2013.
U.S. Appl. No. 12/648,106 Office Action Mailed Sep. 18, 2013.
Wu et al., “Study on the preparation and characterization of biodegradable polylactid/multi-walled carbon nanotubes nanocomposites,” Polymer 48 (2007) 4449-4458.
PCT/US2011/29667 International Search Report and Written Opinion mailed Jun. 1, 2011.
PCT/US2011/67921 International Preliminary Report on Patentability dated Jul. 11, 2013.
Abreu Filho et al., “Influence of metal alloy and the profile of coronary stents in patients with multivessel coronary disease,” Clinics 2011;66(6):985-989.
CA 2757276 Office Action dated Feb. 5, 2014.
CA 2794704 Office action dated Feb. 7, 2014.
CA 2615452 Office Action dated Oct. 8, 2013.
CA 2613280 Office action dated Dec. 10, 2013.
CA 2667228 Office action dated Jan. 22, 2014.
CA 2679712 Office action dated Feb. 24, 2014.
CA 2667228 office action dated May 7, 2013.
CA 2730995 Office Action dated Feb. 20, 2014.
CA 2756386 Office action dated Oct. 24, 2013.
CA 2805631 Office Action dated Jan. 17, 2014.
CN 200880007308.1 Office Action dated Jan. 2, 2014.
CN 200880100102.3 Office Action dated Dec. 11, 2013.
CN 200980136432.2 Office action dated Nov. 4, 2013.
CN 201080024973.9 Office action dated Dec. 20, 2013.
Colombo et al. “Selection of Coronary Stents,” Journal of the American College of Cardiology, vol. 40, No. 6, 2002, p. 1021-1033.
EA 200901254 Office Action dated Jul. 29, 2013.
EA 201001497 Office Action dated Jul. 29, 2013.
EP07756094.4 Office Action dated Jan. 21, 2014.
EP08705772.5 Office Action dated Oct. 30, 2013.
EP09755571.8 Office Action dated Dec. 13, 2013.
EP09798764.8 Search Report dated Sep. 30, 2013.
EP10756676.2Search Report dated Jan. 31, 2014.
EP10756696.0 Search Report dated Oct. 10, 2013.
EP10764884.2 Search Report dated Oct. 28, 2013.
EP10765295.0 Search Report dated Oct. 17, 2013.
EP10800642.0 Search Report dated Mar. 19, 2004.
IL-201550 Official Notification dated Dec. 8, 2013.
IN-6884DEFNP2009 Office Action dated Oct. 31, 2013.
JP-2011-518920 Office action dated Oct. 23, 2013.
JP-2012-503677 Office action dated Nov. 1, 2013.
JP-2012-151964 Office Action dated Dec. 10, 2013.
KR10-2013-7031237 Office action dated Mar. 17, 2014.
Matsumoto, D, et al. Neointimal Coverage of Sirolimus-Eluting Stents at 6-month Follow-up: Evaluated by Optical Coherence Tomography, European Heart Journal, Nov. 29, 2006; 28:961-967.
MX/a/2010/01148 Office action dated Feb. 11, 2014.
PCT/US06/24221 International Preliminary Report on Patentability dated Dec. 24, 2007.
PCT/US06/27321 International Preliminary Report on Patentability dated Jan. 16, 2008.
PCT/US06/27322 International Preliminary Report on Patentability dated Jan. 16, 2008.
PCT/US07/10227 International Preliminary Report on Patentability dated Oct. 28, 2008.
PCT/US07/80213 International Preliminary Report on Patentability dated Apr. 7, 2009.
PCT/US08/11852 International Preliminary Report on Patentability dated Apr. 20, 2010.
PCT/US08/50536 International Preliminary Report on Patentability dated Jul. 14, 2009.
PCT/US08/60671 International Preliminary Report on Patentability dated Oct. 20, 2009.
PCT/US08/64732 International Preliminary Report on Patentability dated Dec. 1, 2009.
PCT/US09/41045 International Preliminary Report on Patentability dated Oct. 19, 2010.
PCT/US09/69603 International Preliminary Report on Patentability dated Jun. 29, 2011.
PCT/US10/28265 International Report on Patentability dated Sep. 27, 2011.
PCT/US10/29494 International Preliminary Report on Patentability dated Oct. 4, 2011.
PCT/US10/31470 International Preliminary Report on Patentability dated Oct. 18, 2011.
PCT/US11/032371 International Report on Patentability dated Oct. 16, 2012.
PCT/US11/051092 International Search Report dated Mar. 27, 2012.
PCT/US11/051092 Written Opinion dated Mar. 27, 2012.
PCT/US11/22623 International Preliminary Report on Patentability dated Aug. 7, 2012.
PCT/US12/33367 International Preliminary Report on Patentability dated Oct. 15, 2013.
PCT/US13/41466 International Search Report and Written Opinion dated Oct. 17, 2013.
PCT/US13/42093 International Search Report and Written Opinion dated Oct. 24, 2013.
PCT/US2011/033225 International Search Report and Written Opinion dated Jul. 7, 2011.
PCT/US2012/60896 International Search Report and Written Opinion dated Dec. 28, 2012.
PCT/US2013/065777 International Search Report and Written Opinion dated Jan. 29, 2014.
U.S. Appl. No. 11/158,724 Office action Mailed Dec. 31, 2013.
U.S. Appl. No. 12/426,198 Office Action mailed Feb. 7, 2014.
U.S. Appl. No. 12/504,597 Office Action Mailed Apr. 1, 2014.
U.S. Appl. No. 12/595,848 Office Action Mailed Oct. 22, 2013.
U.S. Appl. No. 12/601,101 Office Action mailed Feb. 13, 2014.
U.S. Appl. No. 12/729,156 Office Action Mailed Feb. 13, 2014.
U.S. Appl. No. 12/729,580 Final Action dated Nov. 14, 2013.
U.S. Appl. No. 12/738,411 Office Action mailed Feb. 6, 2014.
U.S. Appl. No. 12/751,902 Office Action Mailed Dec. 19, 2013.
U.S. Appl. No. 12/762,007 Final Office action Mailed Oct. 22, 2013.
U.S. Appl. No. 13/014,632 Office action Mailed Jan. 10, 2014.
U.S. Appl. No. 13/340,472 Office action Mailed Jan. 15, 2014.
U.S. Appl. No. 13/384,216 Final Action dated Nov. 6, 2013.
U.S. Appl. No. 13/445,723 Office action mailed Mar. 14, 2014.
Zilberman et al., Drug-Eluting bioresorbable stents for various applications, Annu Rev Biomed Eng., 2006;8:158-180.
CA 2756307 Office action dated Mar. 24, 2014.
CA 2756388 Office Action dated Apr. 14, 2014.
CA 2756386 Office action dated May 16, 2014.
CA 2823355 Office action dated Apr. 14, 2014.
CN 200880020515 Office Action dated Apr. 15, 2014.
CN 200980136432.2 Office action dated Jul. 3, 2014.
EP11772624.0 Search Report dated Jun. 5, 2014.
EP09798764.8 Office action dated Jun. 30, 2014.
ID-W00201003529 Office action dated Apr. 28, 2014.
IN-7740/DELNP/2009 Office Action dated Jul. 29, 2014.
JP-2009-545647 Office Action dated Apr. 22, 2014.
JP-2013-024508 Office Action dated Apr. 24, 2014.
PCT/US2014/025017 International Search Report and Written Opinion dated Jul. 7, 2014.
Putkisto, K. et al. “Polymer Coating of Paper Using Dry Surface Treatment—Coating Structure and Performance”, ePlace newsletter, Apr. 12, 2004, vol. 1, No. 8, pp. 1-20.
U.S. Appl. No. 11/158,724 Office Action Mailed Jun. 25, 2014.
U.S. Appl. No. 12/522,379 Office Action Mailed Apr. 8, 2014.
U.S. Appl. No. 12/729,603 Office Action Mailed Jun. 25, 2014.
U.S. Appl. No. 12/738,411 Office Action mailed May 30, 2014.
U.S. Appl. No. 12/762,007 Final Office action Mailed Apr. 30, 2014.
U.S. Appl. No. 13/086,335 Office action Mailed Apr. 4, 2014.
U.S. Appl. No. 13/090,525 Office action mailed Apr. 11, 2014.
U.S. Appl. No. 11/995,685 Office Action Mailed Jun. 18, 2014.
CN 201210206265.8 Office Action dated Sep. 15, 2014.

Related Publications (1)

	Number	Date	Country
	20080095919 A1	Apr 2008	US

Provisional Applications (1)

	Number	Date	Country
	60862592	Oct 2006	US

Holder for electrically charging a substrate during coating

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

CPC

International Classifications

Term Extension

Abstract